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ABSTRACT 
 
Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer 
death worldwide. Several features are common to all cancers, but particularly two aroused of 
interest to us, namely the capacity of tumour cells to reprogram their energy metabolism and 
inducing angiogenesis. Therefore, the objective of this study was to understand the role of metabolic 
and angiogenic markers in CRC, by studying their expression and establish possible correlations with 
clinicopathological data. To achieve these goals we created a prospective database of CRC patients 
treated at Braga Hospital in the period 2005-2010, with clinical, pathological and follow-up data. 
From surgical specimens of CRC patients submitted to surgical treatment, Tissue Microarrays were 
constructed for subsequent immunohistochemical evaluation. 
 The metabolic markers selected were the Monocarboxylate Transporter (MCTs), particularly 
MCT1 and MCT4 essential for lactate transport across the plasma membrane, so contributing for 
intracellular homeostasia. To better characterize the role of MCTs in CRC metabolism we also 
evaluated the expression of the chaperones CD147 and CD44 and the glycolytic marker GLUT1. The 
angiogenic markers selected were members of Vascular Endothelial Growth Factor (VEGF) family: 
VEGF-A, VEGF-C and the receptors VEGFR-2 and VEGFR-3 with functions of angiogenesis and 
lymphangiogenesis. The expression of metabolic markers on CRC Hepatic metastasis was also 
evaluated in order to assess whether the metabolic profile of CRC was maintained by the metastatic 
cells. In CRC series and CRC Hepatic metastasis series, the correlation with clinicopathological data 
and survival curves were evaluated to assess their potential as prognostic biomarkers.  
The epidemiological results allowed a better knowledge of our population, since CRC 
epidemiological data are scarce in Portugal. Our results, consistent to that observed in the literature, 
clearly demonstrated that CRC is a major problem of public health and that our population can be 
considered a high-risk population for CRC development.  
We have demonstrated that the metabolic markers are overexpressed in human CRC 
samples, when compared with normal adjacent tissues and the same expression pattern was 
observed in CRC Hepatic Metastasis. Also, analysis of the association between expression of the 
MCT isoforms and chaperones and GLUT1 in CRC and CRC Hepatic Metastasis, demonstrated that 
tumour MCT1 positive cases were associated with CD147 plasma membrane expression and  
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between MCT4 and CD147, CD44 and GLUT1. Also, CRC Hepatic Metastasis holds the same 
metabolic profile alterations documented in CRC tissues for MCT4 positive cases. Thus, we can 
conclude that these metabolic markers contribute to the malignant phenotype of CRC and this 
phenotype persists in Hepatic Metastasis. Overexpression of these markers in CRC, compared to 
normal adjacent cells, places them as potential therapeutic targets in CRC and especially in 
metastatic CRC as most of these proteins were not expressed on normal adjacent tissue. When 
analyzing correlations of these markers with epidemiological data we documented associations with 
parameters that reflect a worse prognosis, reflecting the metabolic advantage that these tumour 
cells have acquired, documented by the survival curves of MCT1 and MCT4 with stage IV and stage 
III, respectively, for colon cancer.  
Assessing the expression of angiogenic markers in CRC series, we observed that all 
molecules were overexpressed, reflecting their role in tumour development and progression. When 
we compared CRC tissue and normal adjacent tissue we observed a statistically significant 
correlation for VEGF-C and a tendency for correlation with VEGFR-2, so contributing for tumour grow 
and tumour metastization. Expression of these markers in normal adjacent cells was less 
pronounced for VEGFR-3 than the remaining proteins, making VEGFR-3 an attractive therapeutic 
target since the lower expression in normal tissues will be associated to fewer side effects. When we 
evaluated the correlation of these markers with epidemiological data, we found correlations with 
tumour characteristics that contribute to progression, invasion, metastasis and poorer prognosis, 
documented by the overall-survival curves of VEGF-C and VEGFR-3 with stage III and stage IV for 
rectal cancer.    
 
In conclusion, the results observed in this thesis, in addition to documenting the metabolic 
and angiogenic gain of CRC cells compared to normal adjacent cells thereby contributing to 
proliferative advantage and metastization capacity, also document that the presence of this 
metabolic and angiogenic markers are associated with tumour characteristics that reflects a worse 
prognosis and so worse patient survival. Altogether, these findings support their role as biomarkers 
and potential therapeutic targets in CRC and metastatic CRC. 
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RESUMO 
O Cancro Colorectal (CCR) é um dos tumores mais frequentes, assim, como uma das 
principais causas de morte por doença neoplásica, a nível mundial. Várias características são 
comuns a todos os cancros, mas duas particularmente despertaram o nosso interesse, 
nomeadamente a capacidade de reprogramação do metabolismo celular e a de angiogénese. 
Assim, o objetivo deste estudo foi compreender o papel dos marcadores do metabolismo e de 
angiogénese no CCR, e, estabelecer possíveis correlações com dados clinico-patológicos. De forma 
a alcançar estes objetivos foi construída uma base de dados prospetiva, de doentes tratados por 
CCR, no Hospital de Braga, no período de 2005-2010, onde foram reunidos dados clínicos, 
anatomopatológicos e de follow-up. A partir dos blocos das peças cirúrgicas dos doentes operados, 
foram realizados “Tissue Microarrays” para posterior avaliação imunohistoquímica.  
Os marcadores de metabolismo selecionados foram os Transportadores de 
Monocarboxilatos (MCTs), nomeadamente MCT1 e MCT4, essenciais para o transporte de lactato 
através da membrana plasmática, contribuindo para a homeostasia intracelular. De forma a melhor 
caracterizar o papel dos MCTs no metabolismo do CCR também foram avaliados os chaperones 
CD147 e CD44 e o marcador glicolítico GLUT1. Os marcadores de angiogénese selecionados foram 
membros da família do Fator de Crescimento Vascular Endotelial (VEGF): VEGF-A, VEGF-C e os 
recetores, VEGFR-2 e VEGFR-3, com funções conhecidas em termos de angiogénese e 
linfangiogénese. No caso dos marcadores do metabolismo, foram também avaliadas as expressões 
destes marcadores numa série de Metástases Hepáticas de CRC, com o objetivo de avaliar se o 
perfil metabólico observado no CCR se mantinha nas respetivas metástases. Em ambas as séries, 
foram avaliadas as correlações destes marcadores com dados anatomopatológicos e as curvas de 
sobrevida, de forma a avaliar o seu potencial como marcadores biológicos. 
Os resultados epidemiológicos contribuíram para um melhor conhecimento da nossa 
população, uma vez que estes dados são escassos em Portugal. Os resultados obtidos, 
concordantes com os observados na literatura, demonstraram que o CCR é um problema 
importante de saúde pública e que a nossa população pode ser considerada uma população de alto-
risco para o seu desenvolvimento.        
 Demonstramos que os marcadores metabólicos analisados estão sobre-expressos nas 
amostras do CCR comparativamente com o tecido normal adjacente e que o mesmo padrão de  
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expressão foi observado nas Metástases Hepáticas de CCR. A análise da correlação da expressão 
das isoformas dos MCT com os chaperones e o GLUT1, na série de CCR, demonstrou que o MCT1 
estava associado à expressão plasmática do CD147 e o MCT4 à expressão plasmática do CD147, 
CD44 e GLUT1. Na série de Metástases Hepáticas de CCR o mesmo perfil metabólico foi observado 
para o MCT4. Desta forma podemos concluir que estes marcadores de metabolismo contribuem 
para o fenótipo maligno do CCR e que este se mantem nas metástases hepáticas. A sobreexpressão 
destes marcadores no CCR comparativamente com o tecido normal adjacente coloca-os como 
potenciais alvos terapêuticos no tratamento do CCR em especial no CCR metastizado uma vez que 
estes marcadores não se encontram expressos no tecido normal adjacente. Ao analisarmos as 
correlações destes marcadores com os dados epidemiológicos documentamos a associação com 
características que revelam um pior prognóstico, refletindo a vantagem metabólica que estas células 
tumorais adquiriram, comprovada pelas curvas de sobrevida do MCT1 e MCT4 para o estadio IV e 
III, respetivamente, para o cancro do cólon.  
Avaliando a expressão dos marcadores de angiogénese, na série de CCR, observamos que 
todos estão sobre-expressos o que reflete o seu papel no desenvolvimento e progressão tumoral. 
Quando comparamos o tecido tumoral com o tecido normal adjacente observamos uma correlação 
para o VEGF-C e uma tendência para a correlação com o VEGFR-2, desta forma contribuindo para o 
crescimento e para a metastização tumoral. A expressão destes marcadores no tecido normal 
adjacente foi menos pronunciada para o VEGFR-3, tornando-o um alvo terapêutico atrativo, uma vez 
que esta menor expressão estará associada a menores efeitos secundários. Quando avaliamos a 
correlação com os dados epidemiológicos, encontramos correlações com características tumorais 
que contribuem para a progressão, metastização e pior prognóstico, documentado pelas curvas de 
sobrevida do VEGF-C e VEGFR-3 para o estadio III e IV, respetivamente, para o cancro do recto. 
Em conclusão, os resultados observados nesta tese documentam o ganho em termos 
metabólicos e de angiogénese das células tumorais de CCR em relação ao tecido normal adjacente, 
contribuindo assim para a sua vantagem proliferativa e de metastização, assim como o facto de a 
presença destes marcadores estar associada a características tumorais de pior prognóstico e com 
impacto na sobrevida dos doentes. Estes factos suportam o possível papel destes marcadores de 
metabolismo e angiogénese, como biomarcadores e potenciais alvos terapêuticos no CCR e CCR 
metastizado.  
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1.1COLORECTAL CANCER EPIDEMIOLOGY  
 
  Colorectal cancer (CRC) is the third most common cancer and the fourth most frequent 
cause of cancer death worldwide (1–5), accounting for over 9% of all cancer incidence (6,7). 
Approximately 1 million of new CRC cases are diagnosed every year and about half a million people 
worldwide die due to this cancer (8). Globally, CRC incidence is very variable, with higher rates in 
North America, Australia and Western Europe and lower rates in developing countries (4,9), 
although, in recent years, high CRC rates have also been reported in these countries (10). In terms 
of mortality, geographic disparities have also been observed (4,11). In Western countries, CRC is the 
second most common cause of death from cancer, and despite advances in treatment, mortality 
remains high with metastatic spread to the liver occurring in about 50% of patients (4,12).  
  European countries presents the highest values in terms of CRC incidence and mortality 
(9,10). Data from the World Health Organization (WHO) and National Registries, reveal that CRC is 
the second most common cancer, after lung cancer in males and breast cancer in females (13). 
From 1998 to 2002, in Europe, the incidence of CRC for men and women was 38.5 and 24.6 
(world age standardization (ASR-W)) per 100 000 inhabitants and mortality was, 18.5 and 10.7 
(ASR-W) per 100 000 inhabitants, respectively (14). However, over the past twenty-five years, 
mortality rates among Caucasians have steadily dropped (15). Data from the WHO, between 1997 
and 2007 revealed that CRC mortality decreased around 2% per year from 19.7 to 17.4/100 000 
for men (world standardized rates), and from 12.5 to 10.5/100 000 for women, and these 
decreases in CRC mortality rates in several European countries are likely due to improvement in 
earlier diagnosis and treatment, with a consequent impact in survival  (16).   
 CRC is a growing problem in Portugal, as its mortality rate has been increasing since the 
1980s, between 1993 e 2001 the new CRC annual cases grew by 44% in men (from 2,060 to 
2,975) and 28% in women (from 1,722 to 2,205) and between 1993 to 2005 total cancer mortality 
grew 15.8% (17). Data from the “National Statistic Registry”, revealed that CRC, in Portugal, is the 
second most common cancer, after gastric cancer, with an incidence of 5000/year and a leading 
cause of cancer death (18).         
 In the North of Portugal, data from RORENO (Northern Regional Oncologic Registry) shows 
that, in 2005, CRC was the most prevalent cancer, followed by prostate cancer in males and breast  
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cancer in females (19), and the second cause of cancer death, followed by lung cancer (20). Despite 
improvement in earlier diagnosis and advances in treatment from 2000 to 2005, the number of CRC 
deaths increased at an annual average growth rate of 3% (17).  
 Incidence is generally higher in men, and the risk increases with age, as the majority of 
cases are diagnosed in patients older than 50 years (1,3,4,14), with only 5% of cases recorded in 
patients younger than 40 years (1,4). Advanced CRC prevalence, also increases with age and is 
higher among men than women (4,21). A large study identified CRC as one of the 10 most common 
cancers, diagnosed in both genders aged 20-49 years (22).  
 
 
1.2 COLORECTAL CANCER RISK FACTORS 
 
Literature data concerning hereditary, experimental and epidemiological issues state that 
CRC is a result of elaborated interrelationships between genetic and environmental factors (6,23).  
 
 
1.2.1 ENVIRONMENTAL RISK FACTORS 
 
Evidence suggests that environmental risk factors are of major importance in the cause of 
CRC (17,24) and responsible for the increase in CRC cases  in the last 30 years (17). Those factors 
including cultural, social, and lifestyle factors, nutritional practices, physical activity, obesity, 
cigarette smoking and heavy alcohol consumption are well established environmental risk factors 
(25). In the 1970s, Burkitt proposed the hypothesis that dietary fiber reduces CRC risk, based on 
the observation of low rates of CRC among rural Africans who eat a high-fiber diet (25).  In 2003, the 
European Prospective Investigation into Cancer and Nutrition (EPIC) study reported a linear 
reduction in CRC risk with increasing fiber intake (25,26) and this result was confirmed in 
subsequent studies (27–30). The lost of Mediterranean diet adoption (especially lower consumption 
of cereals and olive oil) and higher energy intake (animal fats, red meat and alcohol) are key diet risk 
factors (17) for CRC. Also, metabolic syndrome, characterized by obesity, insulin resistance and 
hypertension, and a consequence of western dietary and behavior patterns was been demonstrated  
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to contribute to CRC risk (31).  
Beyond dietary factors, lifestyle factors have also been extensively investigated. The second 
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) expert report 
showed that high levels of body fat (BMI >23 kg/m2) or a large waist circumference and lower 
physical activity are associated with increased risk (32–35). Jacobs et al. (32,36) pointed obesity as 
a risk factor for colorectal adenoma development, particularly in men, in short-interval follow up (3 
years). In addition, recent evidence has demonstrated that increasing physical activity in men aged 
over 50, results in a decrease in CRC risk (31,32,35,37).      
 Alcohol is one of the best known and most preventable CRC risk factors (32,33,35,38,39). 
Many epidemiological studies (38,40), but not all (41), have reported a positive association between 
alcohol consumption and CRC risk (32,33,35,38,39).  
 
 
1.2.2 GENETIC RISK FACTORS 
 
Epidemiological studies suggested that approximately 15% of CRCs arise in individuals with 
an inherited predisposition to the disease (18,42). A much smaller proportion of cases, fewer than 
5%, results from gene mutations that are associated with mendelian syndromes; familial 
adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), in this 
setting, CRC risk is very high. The remaining ones are sporadic, without a CRC familiar history 
(18,42).   
 The morphogenesis of CRC is well understood (Figure 1): it develops in a dysplasia-
adenoma-carcinoma sequence (43), that was described by Fearon and Vogelstein in 1990 as a 
linear process from normal mucosa to a small polyp to a large polyp to an invasive cancer (44,45). 
Nowadays, it is know that a total of 4-5 steps have to occur and that these cumulative events are 
more important than the sequence that is followed (46) and is responsible for 80-85% of CRCs (43–
45,47). 
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Figure  1: The adenoma-carcinoma sequence in sporadic and hereditary colorectal cancer (48). 
 
 
In genetic terms, three types of genes are involved in CRC: proto-oncogenes, tumour 
suppressor genes and mismatch repair genes. In molecular terms, there are two major tumourigenic 
pathways leading to CRC: cromossomic instability (CIN)  and microsatellite instability (MSI), 80% and 
15-20% of sporadic colorectal cancer, respectively (43,44,47). In the first pathway, mutations 
accumulate in the KRAS oncogene and tumour-suppressor genes, leading to a progression from 
normal mucosa to adenoma and carcinoma. The second pathway is characterized by mutations in 
mismatch-repair genes. If somatic cells are affected, MSI is responsible for sporadic tumours 
(43,44,47).    
 
 
1.2.2.1 CROMOSSOMIC INSTABILITY PATHWAY 
 
This pathway involves chromosomal instability and is characterized by allelic losses on 
chromosome 5q (APC), 17p (p53), and 18q (DCC/SMAD4), high frequency of allelic imbalance 
involving chromosomal arms 5q, 8p, 17p, and 18q, chromosomal amplifications, and translocations 
(49). This model, besides the previously mentioned tumour suppressor genes alterations,  is also 
characterized by alterations in oncogenes such as KRAS and BRAF (50) (Figure 2). 
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Figure  2: Multistep genetic model of colorectal carcinogenesis (51).         
The initial step in colorectal tumourigenesis is the formation of aberrant crypt foci as a result of mutations in the APC 
gene. Progression to larger adenomas and early carcinomas requires activating mutations of the proto-oncogene KRAS, 
in TP53, and loss of heterozygosity at chromosome 18q. Mutational activation of PIK3CA occurs late in the adenoma–
carcinoma sequence in a small proportion of CRC. CIN is observed in benign adenomas and increases with tumour 
progression.  
 
 
 
1.2.2.1.1 ADENOMATOUS POLYPOSIS COLI GENE 
 
Mutation on Adenomatous Polyposis Coli (APC) gene, a tumour suppressor gene, is present 
in 50 -70% of sporadic CRC (52). This gene acts as a gatekeeper of intestinal epithelial homeostasis 
by restricting cytoplasmic levels of β-catenin, the central activator of transcription in the Wnt 
signaling pathway (50,52–54). At molecular level, APC promotes phosphorylation and subsequent 
degradation of β-catenin by supporting a multiprotein destruction complex, composed of the tumour 
suppressor Axin and the serine-threonine kinases GSK3b and CK1, which (53) (Figure 3).  
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
_________________________________________________________________________
8 
 
 
 
 
Figure  3: A model for the Wnt-signaling pathway (54).  
Panel A depicts the down-regulation of β-catenin transactivation activity in normal colonic epithelial cells. β-catenin 
remains in a complex of Axin/Axil/conductin, APC, GSK3β kinase and casein kinase 1 or 2 (CK1 or 2). In the absence of 
Wnt-signaling, GSK3β and CK1 or 2 kinases become active and phosphorylate β-catenin. The phosphorylated β-catenin 
then binds with F-box protein β-TrCP of the Skp1-Cullin-F-box (SCF) complex of ubiquitin ligases and undergoes 
proteasomal degradation. Some other known genes which are regulated by β-catenin/Tcf-Lef pathway are given here – 
cyclin D1, CDH1, Tcf-1, c-jun, Fra-1, PPARd, Gastrin, uPAR, MMP7, Conductin, CD44, Id2, Siamois, Xbra, Twin and Ubx.  
Panel B shows the role of mutations in the APC or β-catenin protein in the regulation of β-catenin level and its 
transactivation property in colon cancer cells. The mutant β-catenin escapes its degradation through Wnt-pathway and 
becomes stabilized in the cytoplasm. The stabilized level of β-catenin then heterodimerizes with Tcf-Lef transcription 
factor and locates into the nucleus, where it actively transcribes cell cycle related genes causing cellular proliferation.  
 
 
In the case of APC mutations, β-catenin is not directed towards degradation, instead it is 
translocated to the nucleus and is responsible for transcriptional activation of several cell cycle 
regulating genes (cyclin D and c-Myc), genes connected to tumour progression (MMP-7, MMP-26) 
and also the peroxisome-proliferator-activated receptor delta gene (53).  APC gene is connected to 
carcinogenesis at different levels such as cell migration and adhesion (52,55,56); besides the 
function on Wnt pathway, it regulates cell migration due to its role in cytoskeletal regulation (52,55) 
mitosis, by promotion of chromosomal alignment (56) and influencing centrosome duplication (57).  
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1.2.2.1.2 DELETED IN COLORECTAL CANCER GENE  
 
Deleted in Colorectal Cancer (DDC) gene is a tumour suppressor gene (58). Mutation is 
present in 73% of sporadic CRC (52,58). The protein codified by DCC is a transmembrane receptor 
of the immunoglobulin superfamily for netrins, factors involved in axon guidance in the developing 
nervous system; besides this function it also has a role in intracellular signaling, apoptosis, cell cycle 
and cell motility (59,60). There are studies that refer that when mutations are present in this gene, a 
worst prognosis results (52).      
 
 
1.2.2.1.3 TUMOUR PROTEIN 53 GENE 
 
Tumour Protein 53 (TP53) gene is a tumour suppressor gene that encodes p53. Mutation 
on TP53 is present in 60-80% of sporadic CRC (52,61,62). This gene stops cells in G phase until 
DNA repair occurs; if that repair does not occur, cells enter apoptosis (52,63), so mutations in this 
gene are involved in malignant transformation, and are associated with a worse prognosis (52).  
 
 
1.2.2.1.4 KRAS, BRAF AND C-MYC GENE 
 
Besides the previously mentioned genes, mutation on KRAS gene, a proto-oncogene, is 
present in 40-50% of sporadic CRC (43,62) and plays a important role in cell division, cell 
differentiation and apoptosis (51) (Figure 4).  
These mutations are generally observed as somatic mutations. The most frequent types of 
KRAS mutations in CRCs are G-to-A transitions (64) and G-to-T transversions (65). KRAS mutations 
occur in MSI tumours, both in HNPCC and in sporadic CRC, in 40% and 18% of cases respectively 
(66). This mutation occurs in earlier stages of dysplasia-adenoma-carcinoma sequence, being 
associated with adenoma growth (43). Several studies support the importance of mutational 
activation of KRAS in the progression of CRC. KRAS gene codon 12 and codon 13 mutations were 
associated with a mucinous and a non-mucinous phenotype, respectively, but were characterized as  
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more aggressive tumours with a greater metastatic potential (67). Moreover, the frequency of 
associated KRAS and BRAF mutations increased along with the depth of intestinal wall invasion and 
a higher frequency of KRAS mutations was observed in lymph node metastases as compared to the 
primary tumours, suggesting that KRAS mutations are responsible for a more invasive tumour cell 
behavior (66). 
 
 
Figure  4: The RAS signaling pathway (51).  
Growth factors binding to their cell surface receptors activate guanine exchange factors (GEF), such as SOS (son of 
sevenless) that are attached by the adaptor protein GRB2 (growth-factor-receptor bound protein 2). SOS stimulates the 
release of bound guanosine diphosphate (GDP) from RAS, and it is exchanged for guanosine triphosphate (GTP), leading 
to the active RAS-GTP conformation. The guanosine triphosphatase (GTPase)-activating proteins (GAP) can bind to RAS-
GTP and accelerate the conversion of RAS-GTP to RAS-GDP, which terminates signaling. Mutated RAS is constitutively 
active in the RAS-GTP conformation. Activated RAS regulates multiple cellular functions through effectors including the 
Raf–MEK–ERK pathway, phosphatidylinositol 3 kinase (PI3K), RALGDS, RALGDS-like gene (RLG), and RGL2. 
 
 
Mutations of BRAF are associated with increased kinase activity and are present in 9 -11% of 
CRC especially at Dukes’ stage A and B (68). In sporadic CRC with a MSI phenotype, BRAF 
mutations were found in 31-45% of the cases (68–70). Remarkably, a single glutamic acid for valine 
substitution at codon 600 (V600E) accounts for approximately 90% of the BRAF mutations found in  
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human tumours (68), this mutation leads to constitutive kinase activation (71) and with rare 
exceptions, V600E BRAF mutations are found in a mutually exclusive pattern with KRAS mutations, 
suggesting that these genetic events activate a set of common effectors of transformation (72).  
 
Mutation on c-myc gene is present in one third of sporadic CRC, it is essential for 
progression of G1 to S phase and regulation of cellular differentiation. It seems to be associated with 
distal tumours, and discriminate a group of patients who have earlier recurrence after surgery (52).   
 
 
1.2.2.2 MICROSATELLITE INSTABILITY PATHWAY 
 
During each cell division, DNA polymerase makes errors while copying DNA. These mistakes 
are more frequent at the level of repeated sequences, known as microsatellites, and are normally 
repaired by a system called MMR (mismatch repair). Tumours defective in this system accumulate 
mutations and are called MSI. Microsatellites are numerous and dispersed throughout the genome, 
in coding and non-coding regions and the instability of non-coding microsatellites is a good indicator 
of the MSI status (73).  
MSI phenotype (defects in the mismatch repair genes hMLH1 and hMSH2) has been found 
in 10-20% of sporadic CRC (73,74) and in 95% of HNPCC (48). These tumours occur preferentially 
in the right colon, 30% versus 2% when comparing right and left CRC, respectively (74). MSI tumours 
were associated with a better prognosis than MSS (Microsatellite Stable) tumours, and respond 
differently to conventional chemotherapeutic agents used in CRC treatment (73,74). 
 
 
1.3DIAGNOSIS AND STAGING 
 
CRCs are usually diagnosed either by direct endoscopic visualization or by a radiological 
investigation (barium enema, computerized tomography (CT) or CT colonography). For the majority 
of cases, histological confirmation is obtained through endoscopic biopsy; 85% of CRCs are 
adenocarcinomas, 10% are mucinous adenocarcinomas and the remainders are rare histological  
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types such as papillary carcinoma, adenosquamous carcinoma and signet ring cell carcinoma (75).  
Pre-operative staging is central in CRC, on the one hand there are a wide range of clinical 
scenarios and treatment options (75); on the other hand, CRC survival is directly associated with the 
tumour stage at the time of diagnosis; patients with distant metastasis have a poor 5-year survival 
(12%), compared with patients with a localized disease (90%) (76–78). 
A number of imaging modalities are used in the pre-operative staging of CRCs including CT, 
Magnetic resonance imaging (MRI), ultrasound imaging and positron emission tomography (PET) 
(75). 
 
 
1.3.1 COMPUTERIZED TOMOGRAPHY (CT) 
 
This exam is capable of identifying the primary tumour, lymph nodes and other organs 
metastases, but the major limitations of CT is that it does not provide neither histological diagnostic 
neither functional information and hence cannot discriminate between active cancer and scar tissue 
(75).           
 Pre-operative staging with abdominal CT can change the patient treatment plan, by finding 
liver metastases, peritoneal carcinomatosis and locally advanced colon cancer. Although in the past, 
these conditions were considered incurable, nowadays various multi-modality treatments can be 
offered to selected patients (79–81), even in the case of incurable advanced CRC, staging may 
change the treatment plan towards a palliative treatment plan, avoiding surgery in selected patients 
(81,82). 
 Staging with chest CT as a routine procedure before surgery is controversial, mainly due to 
the low incidence of clinically relevant lung metastases and low specificity of chest CT (83). After the 
liver, lung is the most common site for distant metastatic in CRC, and about 10% of CRC patients 
develop pulmonary metastasis (84). However, fewer than 10% of the patients who develop 
pulmonary metastasis are candidates for surgical resection (84,85). According to the National 
Comprehensive Cancer Network (NCCN) guidelines, chest CT is recommended for pre-operative 
staging of CRC patients (84,86,87). On the other hand, Dutch national evidence-based guideline for 
diagnosis and treatment of patients with colorectal metastases states that in the case of lung  
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metastasis, imaging exam could be limited to conventional chest X-ray, based on the low prevalence 
of lung metastases and the occurrence of false-positives at CT (88). 
 
1.3.2 MAGNETIC RESONANCE IMAGING (MRI) 
 
MRI is ideal for rectum as this bowel segment is relatively fixed and for this reason, the use 
of MRI to stage rectal cancers by assessing primary tumour and its relationship to the bowel wall is 
standard and essential in guiding rectal cancer treatment (75).      
 MRI can also be used in the assessment of metastatic liver disease, not only in cases where 
there is some doubt about the nature of the liver lesions but also identifying metastases that have 
not been seen by standard CT and providing a roadmap for surgery in the case of metastatic liver 
disease candidate for surgical resection (75). 
 
 
1.3.3 ULTRASOUND IMAGING 
 
Transrectal ultrasound is a exam that is used to the staging of rectal cancers by assessing 
the tumour, its relationship to the bowel wall and the presence of lymph node metastasis 
(75,89,90). Like MRI, transrectal ultrasound is essential in guiding rectal cancer identifying patients 
that are candidates to the use of pre-operative radiotherapy (75). 
 
 
1.3.4 POSITRON EMISSION TOMOGRAPHY (PET) 
 
PET is capable of identifying cancer earlier than other exams such as CT and MRI. Actually, 
in CRC, the main indications for PET are: assessment of residual mass following treatment and of 
apparently isolated metastatic disease (75). Depending on the tumour type, it can be highly effective 
in assessing treatment response or for detecting disease recurrence. However, in histological CRC 
subtypes, like mucinous carcinoma, due to its low metabolic rate, it is not useful (75). 
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1.3.5 STAGING  
 
The need of stratification patients with CRC in order to establish an appropriate treatment 
results in the first clinical staging system proposed by Dukes and Jass, for rectal cancer, based on 
the extent of the primary tumour and presence/absence of  lymph node involvement (91–94). 
However, this staging system lacks some important tumour characteristics, such as extent of lymph 
node involvement and tumour grade. Later, in 1987, Jass added two new characteristics, the nature 
of the expanding front of the tumour and the presence/absence of lymphocytic infiltration at the 
advancing edge, thus addressing some of those absences (95). In the following years, as new 
factors became known, the Dukes’classification has been repeatedly modified by others (Kirklin, 
Astler and Coller, etc.) (91).       
 Nowadays, TNM staging is the most widely used system, it classifies the extent of cancer 
based on anatomical information about the size and extent of primary tumour (T), the regional lymph 
node status (N) and the distant metastases (M), grouping the cases with similar prognostic (91,96). 
The system is maintained collaboratively by the International Union for Cancer Control (UICC) and 
the American Joint Committee for Cancer (AJCC), resulting in periodical and simultaneously 
publication of the TNM Classification of Malignant Tumours and the AJCC Cancer Staging Manual. 
The 7th revision of TNM staging was recently published by the AJCC and UICC, and became 
operational starting on 2010.01.01 (91,97). 
The staging system is categorized from Stage 0 through stage IVB (Table I) and correlates 
with patient prognosis (Table II). Stage I disease includes tumours with tumour depth penetration 
into the submucosa (T1) or the muscularis propria (T2). In stage IIA–IIC CRC, tumour penetration 
can extend from muscularis propria to adhere to other organs however, there is no lymph node 
involvement. Nodal involvement begins in stage IIIA–IIIC regardless tumour depth penetration. 
Finally, stage IVA–IVB, incorporates one distant organ involvement (M1a) or greater than 1 
organ/peritoneal involvement (M1b), independently of tumour depth penetration and regional lymph 
nodes involvement (98). 
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Table I: 7th revision of the TNM Staging of Colorectal carcinoma [Adapted from (97)]. 
 
Primary Tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into pericolorectal tissues 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
 
Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1–3 regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in 2–3 regional lymph nodes 
N1c 
Tumour deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or 
perirectal tissues without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4–6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
 
 
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or site 
M1b Metastases in more than one organ/site or the peritoneum 
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Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
 
T2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-T2 N1/N1cM0 M0 
 
T1 N2a M0 
IIIB T3-T4a N1/N1cM0 M0 
 
T2-T3 N2a M0 
 
T1-T2 N2b M0 
IIIC T4a N2a M0 
 
T3-T4a N2b M0 
 
T4b N1-N2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
 
 
 
Table II: TNM Staging of Colorectal Carcinoma and 5‐Year Survival by Stage [Adapted from (98)]. 
 
Stage 5‐Year Survival 
I 93.2% 
IIA 84.7% 
IIB 72.2% 
IIC  
IIIA 83.4% 
IIIB 64.1% 
IIIC 44.3% 
IVA 8.1% 
IVB 8.1% 
 
Note: Five year percentages based on data prior to institution of 7th edition, AJCC staging guide (99). 
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In the last years, there has been a growing interest focusing on the role of non-anatomic 
markers as prognostic and treatment response in cancer patients (91). These molecules might allow 
more accurate CRC staging, improving patients selection for multimodal therapy and sparing 
patients from unnecessary procedures (77,78). However, besides TNM, few stage markers have 
been validated as diagnosis criteria worldwide (77,78). 
 
 
1.4 CANCER METABOLIC BEHAVIOR 
Reprogramming of energy metabolism is one of the hallmarks of cancer, which was recently 
added to sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion, metastasis and evading immune 
destruction (100).          
 Normal cells and tumour cells differ markedly in energy metabolism; normal cells use 
glucose as their primary energy source. In the presence of adequate oxygen supply, normal cells 
completely oxidize glucose, a process that involves cytoplasmic glycolysis, mitochondrial citric acid 
cycle and electron transport chain/oxidative phosphorylation (OXPHOS). Consequently, normal cells 
drive the maximum possible energy from glucose by fully oxidizing the molecule to CO2 (Figure 5). 
 When the oxygen supply is disrupted, normal cells turn their metabolism to anaerobic 
glycolysis, due to mitochondrial function suppression, as a consequence of oxygen absence. This 
metabolic pathway has lactate as the end product and conversion of pyruvate, the glycolytic end 
product, into lactate is mandatory for continued operation of glycolysis in the absence of oxygen. 
Consequently, the regeneration of NAD+, the coenzyme for glyceraldehyde-3-phosphate 
dehydrogenase, is ensured. Contrary to “aerobic glycolysis”, this pathway only produces a fraction of 
energy from glucose (Energetic yield: 2 ATPs/glucose molecules). Thus, this less efficient energetic 
pathway is adopted by normal cells only under anaerobic conditions (102) (Figure 5). 
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Figure  5: Schematic representation of Warburg effect (101).                           
Represents the differences between OXPHOS, anaerobic glycolysis, and “aerobic glycolysis”. 
 
 Unlike normal cells, tumour cell metabolism depends mainly on this metabolic pathway, 
even in the presence of oxygen. This phenomenon, "aerobic glycolysis" or "Warburg effect”, was first 
described almost one century ago, by the Nobel Prize winner Otto Warburg, it was the first tumour-
metabolism specific alteration described and consists of an increase in glycolytic rate that is 
maintained even in the presence of adequate levels of oxygen. As a consequence, tumour cells are 
producing lactate at higher levels compared to non-malignant tissue (103–106).    
 In order to maintain the high rates of glycolysis, cancer cells use elevated amounts of 
glucose as energetic source (107), with increase in glycolytic flux (103,108–112), mainly caused by 
upregulation of numerous glycolysis-related genes in the majority of human cancers (104).  
 There are several reasons why enhanced “aerobic glycolysis” constitutes an advantage for 
tumour growth (113):           
 - Tumour cells are able to survive in conditions of low oxygen tension, that would be lethal 
for cells that depends mostly on aerobic metabolism to generate energy (113,114).   
 - The acidic tumour microenvironment, resulting by the acids produced by cancer cells, 
namely lactic acid (115) is associated with tumour aggressiveness features, such as growth,  
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increased survival, migration, invasion, and angiogenesis (104,116,117), and suppress anticancer 
immune effectors (118). Moreover, lactate can be taken up by stromal cells to regenerate pyruvate 
that can be either extruded to refuel the cancer cell or can be used for OXPHOS (115).  
 - Tumours are able to metabolize glucose, through the pentose phosphate pathway, to 
generate NADPH thus supplying cell’s anti-oxidant defenses against a hostile microenvironment and 
chemotherapeutic agents (119). NADPH can also contribute to fatty acid synthesis.   
 - Cancer cells use intermediates of the glycolytic pathway for anabolic reactions: glucose 6-
phosphate for glycogen and ribose 5-phosphate synthesis, dihydroxyacetone phosphate for 
triacylglyceride and phospholipid synthesis, and pyruvate for alanine and malate synthesis (119). 
Moreover, pyruvate may enter a truncated tricarboxylic acid cycle. The resultant acetyl-CoA is 
exported from the mitochondrial matrix and becomes available for the synthesis of fatty acids, 
cholesterol, and isoprenoids (113).         
 - Reduced ATP generation in mitochondria is a compromise that tumour cells have to make 
in order to initiate oncogenic transformation by partially inhibiting OXPHOS, consequently, the 
generation of reactive oxygen species (ROS) increase (120), causing mutations in proto-oncogenes 
to initiate tumourigenesis (102).         
 Since enhanced glycolysis in cancer is associated with lactate production and secretion 
(103,109–112) and despite the large amounts of lactic acid produced only the interstitial pH of 
tumours is low, while the intracellular pH of tumours is either normal or higher than normal tissues 
(109–111), tumour cells must find a way to eliminate lactic acid to prevent cellular acidification and 
apoptosis (103,104,112). This is achieved by specific transporter upregulation like proton pumps, 
sodium-proton exchangers, bicarbonate transporters, and monocarboxylate transporters (MCTs) 
(109).             
 By counteracting intracellular acidification, the export of lactic acid leads to acidification of 
the extracellular milieu which turns to be advantageous to tumour progression for two reasons; first 
extracellular acidification may kill adjacent normal cells, allowing tumour cells to spread, second it 
facilitates angiogenesis and metastization through upregulation of molecules involved in tumours 
growth, progression and metastization such as Vascular Endothelial Growth Factor (VEGF), Hypoxia-
inducible Factor 1, (HIF-1α), and hyaluronan and its receptor CD44 (103,121). Some studies report 
that elevated lactate levels correlate with increasing incidence of metastases (122), radioresistance  
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(123) and poor prognosis, particularly poor overall survival and poor disease-free survival 
(104,123,124) in human cervical cancers (125–127), head and neck cancer (111), brain cancer 
(128,129) non-small-cell lung cancer (130) adenocarcinoma lung cancer (131) and CRC (132,133). 
 
 
1.4.1 MONOCARBOXYLATE TRANSPORTERS  
 
The monocarboxylate transporter (MCT) family is presently composed by 14  members, and 
is encoded by the SLC16 gene family (134,135). Currently, only four members (MCT1-MCT4) of the 
MCT family have been demonstrated to transport aliphatic monocarboxylates, including lactate, 
pyruvate and ketone bodies (135,136). Besides the previously mentioned monocarboxylates, MCTs 
also transport the branched-chain oxo-acids derived from leucine, valine and isoleucine, and the 
ketone bodies acetoacetate, β-hydroxybutyrate and acetate. Consequently, MCTs play a central role 
in metabolism and are critical for metabolic communication between cells (136). 
 
MCT1 has a broader distribution and transports a wider range of substrates when 
compared to other family members. The main function of this transporter has been associated with 
the uptake or efflux of monocarboxylates  through the plasma membrane, according to cell 
metabolic needs and behaving as a high affinity transporter for L-lactate, but not for D-lactate, as 
well as for pyruvate, acetate, propionate, D,L-β-hydroxybutyrate and acetoacetate (134,135). It has 
also been implicated in the transport of butyrate and propionate in human colonocytes, the principal 
energy substract for these cells (127,135,137).  
 
MCT4 demonstrates several similarities to MCT1, namely tissue distribution, regulation and 
substrate/inhibitor specificity. The principal difference between these isoforms lies in tissue specific 
localization and substrate affinities. MCT4 is predominantly expressed in highly glycolytic cells such 
as white muscle and white blood cells (135,138) and also strongly expressed in placenta, exporting 
lactic acid rapidly from the fetal to the maternal circulation, thus suggesting that its physiological 
function is lactate efflux (139). Another difference is that MCT4 shows a lower affinity for substrates, 
than MCT1 (138,140). In fact, MCT4 will not only be important for the acid-resistant phenotype, but  
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also for the hyper-glycolytic phenotype, by exporting newly formed lactate, allowing continuous 
conversion of pyruvate to lactate, so, and, therefore, continuous aerobic glycolysis (135). 
In the past few years some studies reported abnormal expression of MCTs, particularly in 
solid tumours, however, with contradictory conclusions (141). CRC provides intriguing information 
regarding MCT expression in cancer. Koukourakis et al. demonstrated that both membrane and 
cytoplasmic MCT1 expression was seen in both normal colonic tissue as well as in colonic tumour 
cells (127,142,143). In our previous results, Pinheiro et al. have demonstrated an increase in MCT1 
and MCT4 in CRC compared with normal colonic epithelium (108,127). On the other side, Lambert 
et al. described a decrease in MCT1 expression during transition to malignancy (108,127,144).  
 
 
1.4.2 MCT REGULATION BY CHAPERONES 
 
Functional expression of MCTs is regulated by accessory proteins (Figure 6), such as 
Cluster of Differentiation 147 (CD147), also known as Basigin (BSG) or Extracellular Matrix 
Metalloproteinase Inducer (EMMPRIN)  that are involved in trafficking and anchoring of plasma 
membrane proteins (135).  
 
Figure 6: MCT1 and MCT4 regulation  
(Blue boxes indicate upregulation of the specific MCT subtype while green boxes indicate a downregulation) (127). 
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CD147 is a broadly distributed plasma membrane glycoprotein and belongs to the 
immunoglobulin superfamily (145). This chaperone is ubiquitously expressed on the cell surface, 
with the highest levels found in metabolically active cells such as lymphoblasts and cancer cells 
(146,147). CD147 promotes extracellular matrix degradation, tumour growth and metastasis of 
cancer cells through increasing production of hyaluronan (148), and stimulating the production of 
multiple matrix metalloproteinases (MMPs) by fibroblasts, endothelial cells and cancer cells and so 
increasing the invasiveness of tumour cells (149–154). CD147 also stimulates angiogenesis by 
upregulation VEGF expression (155) as well as its main receptor VEGFR-2 in both cancer cells and 
endothelial cells (156). 
Regulation of MCT1 and MCT4 by CD147, was supported by evidence on human and in 
vitro studies (104,135,157–161). Besides the role of CD147 as chaperone for MCT1 and MCT4 
activity, these MCT isoforms also have been implicated in CD147 membrane expression 
(135,157,160).  Thus, the contribution of MCTs to the malignant phenotype is not limited to their 
own function as lactate transporters and pH regulators, but through its role in CD147 expression 
MCTs may also have indirect roles in tumour growth, invasion and angiogenesis (135,162–164). 
 Like MCT, studies on CD147 expression in CRC are limited. High expression of CD147 has 
been observed in various carcinomas including colorectal cancers (149,165–167);  breast cancers 
(148,168–170), hepatomas (171), oesophageal (179) and cervical squamous cell carcinomas 
(172), ovarian carcinomas (173) and gastric cancer (174). On the other hand, van der Jagt et al. 
observed that CD147 expression was higher in normal tissue compared to tumour tissue (175). 
Elevated CD147 expression has also been shown to correlate with the progression of various 
malignancies (148,150,151,166,168,171–173,176). Zheng et al. (177) documented that CD147 
expression was stronger in CRC and metastatic carcinoma than non-neoplastic superficial 
epithelium. Also, Buergy et al. and Jin et al. reported that a high relative CD147 expression was 
associated with advanced tumour stage and with metastatic disease (178,179). Baba et al. observed 
that blocking CD147 led to an increase in cell death (180).  
 
CD44 was originally described as an antigen on red blood cells and platelets, and 
subsequently recognized as a lymphocyte homing receptor (181,182). 
It is a transmembrane glycoprotein that acts mainly as a receptor for hyaluronan but can  
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also bind to other extracellular matrix ligands like chondroitin sulphate, heparan sulphate, 
fibronectin, serglycin, osteopontin but with lower affinity (181,182). It’s main function is 
communication of cell-matrix interactions (181,182) but also participates in other cellular processes, 
including growth, survival, differentiation, and motility (183). Recently it was found that CD44 may 
also act as a chaperone for MCT expression (162).   
 CD44 is encoded by a single gene containing 20 exons, 10 of which are variant exons 
inserted by alternative splicing (181),some of these variant isoforms are up-regulated in cancers 
(181,184–187) and has been implicated in numerous aspects of cancer progression (184–187). 
 Additionally, parallel analysis of CD44 and MCTs expressions in human cancer, show that 
CD44 is associated with MCT1 in lung cancer (104) and both MCT1 and MCT4 in prostate cancer 
(188). Several studies have suggested an important biological role for CD44 in tumour progression, 
metastasis and as a potential clinicopathological marker of disease progression for colorectal cancer 
(189–194) breast cancer (195), pancreatic cancer (196) gastric cancer (197) and esophageal 
carcinoma (198,199).  
Some studies correlates variant isoforms of CD44 expression with a poor prognosis in colon 
cancer (200–202) and that can be a molecular marker for colorectal cancer and for the presence of 
micrometastasis in regional normal lymph node (202), but different conclusions have been achieved 
about an potential relationship between variant CD44 expression and the prognosis of patients with 
CRC  (181,203–205) and more recent results suggest either no role or a worse clinical outcome for 
CD44 variant isoforms expression (192,206–208).   
 
 
1.4.3 GLUCOSE TRANSPORTERS  
 
Cancer cells, in order to continue their uncontrolled growth and proliferation, must 
compensate the inefficient extraction of energy from glucose, this is achieved by overexpression of 
glucose transport through plasma membrane (209–211), that is mediated by a family of facilitated 
glucose transporter proteins named (GLUT 1–14) (209,212). This up-regulation may be a 
constitutive feature of the malignant phenotype in many cancers or may result from an adaptative  
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increase in GLUT1 expression, a hypoxia-responsive transporter, due to local hypoxia in the tumour 
microenvironment (213,214).        
 The GLUT family is expressed in the membrane of nearly all cell types; GLUT1, a high-
affinity glucose transporter, is restricted to erythrocytes and blood-tissue barriers such as the blood-
brain and blood-nerve barriers (210,212,213).      
 Overexpression of GLUTs has been observed in various cancers (209,210), namely breast, 
lung, kidney, urinary bladder, stomach, colorectum, endometrium, thyroid, head and neck, liver, 
ovary, salivary gland, and prostate cancer (210,212,215) due to a high metabolic rate and fast 
growth environment. The lack of GLUTs expression in  benign epithelial tissues makes it a potential 
marker for malignant transformation (210,214,216).       
 Other studies revealed  a correlation between GLUT1 expression level and the grade of 
tumour aggressiveness (209,212,213,217,218), increased proliferative activity and energy 
requirements (212) suggesting that GLUT1 expression may correlate with prognostic (209,213,219).  
 
 
1.4.4 MCT TARGETING THERAPY IN CANCER  
 
Tumour cells intracellular pH homeostasis and subsequent extracellular acidosis have been 
considered a key factor essential for both cell transformation and progression of the neoplastic 
process (220). MCT inhibition, by affecting pH homeostasis, will have a direct impact in cellular and 
extracellular balance with an important effect on cell viability. MCT inhibition not only induces 
apoptosis due to cellular acidosis, but would also lead to reduction in tumour angiogenesis (221), 
invasion  (222), and metastization (223) (Figure 7).  
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Figure  7: Model for therapeutic targeting of lactate-based metabolic symbiosis in tumours (124).          
Hypoxic tumour cells depend on glycolysis to produce energy. Lactate, diffuses along its concentration gradient toward 
blood vessels. By contrast, oxygenated tumour cells import lactate (mediated by MCT1) and oxidize it to produce energy. 
Upon MCT1 inhibition, oxidative tumour cells switch from lactate oxidation to glycolysis, thereby preventing adequate 
glucose delivery to glycolytic cells, which die from glucose starvation.  
 
 
This hypothesis was already proven both in vitro and in vivo in various cancers models, 
namely in gliomas (224,225) and neuroblastomas (226). In order to investigate a novel method to 
enhance radiosensitivity of gliomas, namely by modulating the metabolite flux immediately before 
radiotherapy, Colen et al. (224) disrupted cell metabolic balance with α-cyano-4-hydroxycinnamate 
(CHC) concluding that this inhibitor of MCT activity supported the usefulness of metabolic 
remodeling before low-dose radiation-based glioma therapy. Also Mathupala et al. (225) in malignant 
gliomas, demonstrated that small interfering ribonucleic acid (siRNA) specific for MCT1 and MCT2, 
in U-87 MG cells, reduced lactate efflux by 30% individually and 85% in combination, with a 
concomitant decrease of intracellular pH. Additionally, with prolonged silencing, cell viability was 
reduced by 75% individually and 92% in combination. Fang et al. (226) also pointed MCT1 as a 
therapeutic target in neuroblastoma.        
 Also, inhibition studies on CD147 with RNAi have demonstrated significant decreases in 
invasiveness, MMP secretion, multidrug resistance and increased cell death. Inhibition by a mouse  
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monoclonal antibody, who disrupts CD147–MCT1 association, led to specific cancer cell death while 
sparing normal fibroblast (227). 
Since MCT inhibitors have the potential for altering metabolism, intracellular pH, and 
angiogenic response, they are promising therapeutics targets but we cannot forget the deleterious 
whole-body effects that they can cause and so it is mandatory to evaluate toxicity to normal tissue 
(227). Currently a clinical trial is ongoing based on the antitumoural effect of CHC as MCT1 
inhibitor, a related orally administered compound, AZD3965, is currently entering PhaseI/II clinical 
trials for advanced solid tumours (228).   
 
 
1.5 TUMOUR ANGIOGENESIS 
Angiogenesis plays a key role in tumourigenesis and metastatic processes (4,229–234). It 
consists in the formation of new blood vessels from the endothelium of pre-existing vasculature 
(232,235) but recruitment and in situ differentiation of bone marrow-derived endothelial progenitor 
cells are also involved (232); it includes proliferation and migration of activated endothelial cells to 
reach remote targets, assembly of these cells into new capillary tubes, followed by synthesis of a 
new basement membrane and maturation with formation of a vascular lumen (232).  
 During tumourigenesis, the appropriate balance between proangiogenic and antiangiogenic 
molecules which arise from cancer cells and stromal cells is lost (4,232,235–239). This “angiogenic 
switch” is triggered by several factors including: (a) oncogene-mediated tumour expression of 
angiogenic proteins including VEGF, hepatocyte growth factor (HGF), fibroblast growth factor (FGF), 
platelet derived growth factor (PDGF), endothelial growth factor (EGF), lysophosphatic acid (LPA), 
and angiopoietin (Ang), (b) metabolic and/or mechanical stress, (c) genetic mutations, (d) the 
immune response, and (e) hypoxia, maybe the most prominent. Tumour-angiogenesis therefore 
depends on tumour type, localization, growth and stage of disease and contributes to tumour 
growth, invasion, and metastization (4,235,238,240–244).    
 Oxygen tension is the key regulator of VEGF expression, predominantly via the hypoxia-
inducible factor/von Hippel-Lindau tumour suppressor gene pathway. As a result of tumour growth  
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and insufficient vascularization, tumours often are accompanied by a decrease in oxygen tension 
(238) and under these hypoxic conditions, non-hydroxylated HIF accumulates, translocates to the 
nucleus initiating transcription of various genes that play a central role in angiogenesis. Genes 
induced by HIF include: VEGF, PDGF, transforming growth factor-β (TGF-β), TGFα, epidermal growth 
factor receptor (EGFR), insulin-like growth factor 2 (IGF2), MMP1, stromal cell-derived factor 1 
(SDF1), GLUT 1, carbonic anhydrase 9 (CAIX), and activin B (238,245,246).    
 Tumour angiogenesis is essential to allow neoplastic mass development favoring access to 
the blood components, and also strengthening the vascular routes in the metastatic process 
(4,241,242,244,247,248). Neovascularization as a whole promotes tumour growth by supplying 
nutrients, oxygen and releasing growth factors that promote tumour cell proliferation 
(4,232,239,244,249,250). Hypoxia in solid tumours occurs at a distance of ≥ 70 µm from 
functional blood vessels and tumours do not exceed a volume of 1-2 mm3 without induction of 
angiogenesis (4,250). The onset of angiogenesis precedes an exponential phase of tumour growth 
and local organ invasion. The velocity of angiogenic capillary growth ranges from 0.223 to 
0.8 mm/day (248,251). During this expansion, cancer cells grow as a cuff around each new 
microvessel with a thickness of 50-200 µm. In this configuration, one endothelial cell supports the 
metabolic needs of 5-100 cancer cells (248,252). Eventually, invading blood vessels occupy 1.5% of 
the tumour volume (248).          
 Intratumoural vasculature density is associated directly with cancer cell entrance into the 
systemic blood circulation, with the ability of cancer cells to invade locally normal anatomic 
structures and metastasize in distant organs (4,240).       
 VEGF, a key mediator of angiogenesis, is overexpressed in many tumour types, and has 
been associated with poor prognosis (233,253), although the role of angiogenesis as a prognostic 
factor remains controversial (4,254,255). An association between increased angiogenesis and an 
increased incidence of metastases and a subsequent decrease in survival curve rates was observed 
for the vast majority of solid tumours (2,4,12,240,244,249).     
 Several studies revealed that high angiogenic activity in CRC was correlated with aggressive 
histopathological features such as: parietal invasion, tumour stage, tumour differentiation, metastatic 
potential and poor patient survival (1,4,254,256). This data were confirmed by Tanigawa et al. (249) 
that also have document a inverse relationship between tumour vascularity and patient survival.  
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Gurzu et al. (254) added that augmented angiogenesis in CRC was higher in early-stages of tumour 
proliferation but was not a progressively increasing process, having rather an oscillating character. 
However, other studies revealed that angiogenesis does not provide any significant information 
(4,231,232,254). These controversial findings may be credited to the lack of standardization of the 
different methods of counting tumour blood vessels and to the different cut-offs used to define 
relevant parameters to consolidate the results and, lastly, to the different antibodies used 
(4,231,232,254). Despite the debates, assessment of tumour angiogenesis may be particularly 
useful in prognostic classification of patients with apparent early cancer by conventional tumour 
staging, although some may still develop early recurrence or metastasis (4,232). De Vita et al.  
(240) observed that highly angiogenic tumours were associated with the presence of lymph node 
invasion. Nevertheless, a higher percentage of patients with node-positive colon cancer than those 
without will experience recurrence and might benefit from anti-angiogenic adjuvant therapy. Thus, 
angiogenesis can be used to identify a subset of patients at high risk for recurrence regardless of 
their lymph node involvement (249) and so the most important clinical implication of tumour 
angiogenesis is probably the development of anti-angiogenic therapy (4,232). 
 
 
1.5.1 THE VASCULAR ENDOTHELIAL GROWTH FACTOR FAMILY  
 
In mammals, VEGF family consists of VEGF-A, B, C, D (Figure 8) and placental growth 
factor 1 and 2 (PlGF1 and 2).  
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Figure  8: VEGF Family and their Receptors (257).  
 
VEGF-A, is a key inducer of tumour angiogenesis (234,258,259),  it belongs to a subfamily 
of secreted, dimeric glycoproteins of approximately 40 kDa, which in turn belongs to the PDGF 
superfamily (259–261). VEGF-A exists as multiple isoforms; VEGF121, VEGF145, VEGF162, VEGF165, 
VEGF165b, VEGF183, VEGF189 and VEGF206, that results from alternative splicing (259,260,262,263). 
The isoforms VEGF121, VEGF165, and VEGF189 are preferentially expressed in VEGF producing cells 
(264), being VEGF165 the most predominant isoform (259–261,265) and represents the major 
angiogenic form (261). VEGF121 is readily diffusible but apparently has no important physiological role 
and VEGF189 is tightly matrix-bound due to interactions with heparin sulfate proteoglycans (261).  
             
 VEGF-B, which is similar to VEGF-A in its amino acid sequence (approximately 43% 
identical), is mitogenic for endothelial cells and can form heterodimers with VEGF-A, being involved 
in angiogenesis in muscle and heart (266). 
 
VEGF-C and VEGF-D affect primarily the development of the lymphatic vasculature and 
PIGF is primarily expressed in the placenta and its levels are inversely correlated with preeclampsia, 
but it is also detected in non negligible amounts in the heart and lungs (267–270). 
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All VEGF molecules/ligands transduce their signal through their binding to VEGF receptor -1, 
-2 and -3 on vascular endothelial cells (Figure 8). This distribution on endothelial cells accounts for 
the selectivity and specificity of action of VEGF. The three VEGF receptors are related to the PDGFR  
(α and β), the FGF receptors (1–4), the stem cell factor receptor (Kit), the Flt ligand receptor (Flt-3), 
and the colony stimulating factor-1 receptor (CSF-1R), all of which contain extracellular 
immunoglobulin domains and a kinase insert (271). 
 
VEGFR-1 plays a negative role in angiogenesis in the embryo, most likely by trapping VEGF, 
but a positive role in adulthood. VEGFR-1 is expressed not only in endothelial cells but also in 
macrophage-lineage cells, and promotes tumour growth, metastases, and inflammation (272). 
Activation of VEGFR-1 is implicated in the increased expression of urokinase type of plasminogen 
activator and plasminogen activator inhibitor-1 in endothelial cells, that plays a role in extracellular 
matrix degradation and cell migration (271), although no direct proliferative or cytoskeletal effects 
was recognized (271,273). 
 
VEGFR-2 is the key molecule for VEGF signaling in tumour micro-environment, as several 
cascades emanating from the VEGF/VEGFR-2 complex regulate critical angiogenic responses of 
endothelial cells (259), namely proliferative and increase of vascular permeability (259,260).  
   
VEGFR-3 plays a key role in remodeling the primary capillary plexus in the embryo and 
contributes to angiogenesis and lymphangiogenesis in the adult. This receptor occurs in embryonic 
vascular endothelial cells but is restricted to lymphatic vessels in the adult (271,274). Inactivating 
mutations in the catalytic loop of the kinase domain of VEGFR-3 lead to a human hereditary 
lymphedema, the Milroy’s disease,  that is characterized by a chronic and disfiguring swelling of the 
extremities owing to defective cutaneous lymphatic vessels (271). 
 
 
1.5.2 ANTIANGIOGENIC THERAPY 
As previously mentioned one important clinical implication of tumour angiogenesis is 
probably the development of anti-angiogenic therapy (4,232). The participation of angiogenesis in  
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the pathogenesis of neoplastic disease has been described in many papers (275–278); the 
presence of VEGF has been found in cancers of the thyroid (279,280), bronchus, stomach, colon, 
breast, ovary, kidney, and urinary bladder (280). VEGF mRNA expression has been demonstrated in 
malignant tumours of the brain, esophagus, stomach, CRC, liver, breast, ovary, kidney, and urinary 
bladder (281,282). High VEGF concentrations in the blood have been found in patients with 
esophageal cancer (283), CRC, breast cancer (284), ovary (285), uterus (286), bone (287), and 
hormone-resistant prostate cancer (288). Also, several studies reports the connections between the 
degree of VEGF expression with tumour aggression and prognosis in patients with cancer of the 
uterus, ovary (289), breast (289,290), stomach (291), melanoma (292), head and neck neoplasms 
(289), and small cell lung cancer (290). Similarly, high VEGF expression coexists with worse survival 
time and an increased probability of recurrence of malignant CRC and kidney neoplasms (289). 
 Antiangiogenic therapy is based on: (a) inhibitory effects of proangiogenic ligands and their 
receptors; (b) Stimulation or delivery of angiogenesis inhibitors; and (c) direct destruction of 
neoplastic tumour vasculature (275) (Figure 9).  
 
Figure  9: Strategies to inhibit VEGF signaling (293).                                               
These include monoclonal antibodies targeting VEGF-A (a) or the VEGF receptors (b, c). Chimaeric soluble receptors 
such as the 'VEGF-trap' (domain 2 of VEGFR-1 and domain 3 of VEGFR-2 fused to a Fc fragment of an antibody) (d). 
Additional extracellular inhibitors are aptamers (e) that bind the heparin-binding domain of VEGF165. Additional 
strategies to inhibit VEGF signaling include antisense and siRNA targeting VEGF-A or its receptors. 
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Practical applications of monoclonal antibodies anti-VEGF (bevacizumab, ranibizumab) have 
already been found, for example in CRC patients with hepatic metastases (275,294,295). Through 
the development of anti-angiogenic therapy, CRC prognosis is improving (4,232,296–298), the 
median survival of patients with metastatic CRC (mCRC) is approximately 6 months. Palliative 
chemotherapy considerably improves treatment outcome, with 5-fluorouracil plus irinotecan and/or 
oxaliplatin extending median overall survival to approximately 20 months (4,299). Thus, in the past 
decade, the median overall survival of patients with mCRC has increased from 12 months to 
approximately 20 months mainly due to the development of new combinations with standard 
chemotherapy (4,300). Currently, anti-angiogenic treatment can prolong the survival time by some 
months, however, the results are not reproducible for all cases (4,254). There have been clinical 
trials that show as many as 94% of invasive carcinomas and 88% of in situ carcinomas having a 
complete response (4,301). Unfortunately, there are no tumour characteristics or molecular 
markers, at present, that help to identify patients who are likely to benefit from anti-angiogenic 
treatment (4,302).  
Bevacizumab (BV) is a monoclonal antibody against VEGF with anti-angiogenic properties, 
and several clinical trials supported the use of BV in the first-line treatment of mCRC (4,303,304). 
BV is typically used in combination with other chemotherapeutic agents such as oxaliplatin, 
irinotecan, leucovorin, and 5-fluorouracil (5-FU) for treatment of patients with mCRC (4,303,305). In 
addition to its direct anti-angiogenic effects, BV may also improve the delivery of chemotherapy by 
changing tumour vasculature and decreasing the elevated interstitial pressure in tumours (4,302). 
When combined with standard chemotherapy regimens, it has been associated with significant 
improvements, compared with chemotherapy alone, in the efficacy end points of overall survival, 
progression-free survival, and response rates in patients with mCRC, and for some facilitates 
secondary resections (4,306). Jubb et al. (307) demonstrated that in patients with mCRC, the 
addition of BV to irinotecan, 5-FU/leucovorin (IFL) improves survival regardless of the level of VEGF 
expression. The addition of BV to IFL resulted in a statistically significant increase in median overall 
survival of 4.7 months, and in a median progression-free survival of 4.4 months (308). 
BV ultimately achieved “Food and Drug Administration” (FDA) approval in 2004 as a first-
line treatment for mCRC in combination with chemotherapy, based on its statistically and clinically   
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meaningful benefits on progression-free survival and overall survival (309).      
Ranibizumab (which binds to and inhibits a number of subtypes of VEGF-A) received FDA 
approval in 2006 for the treatment of diabetic macular oedema (310).      
 Apart from monoclonal antibody, antagonists of VEGF receptors have been used with great 
success in regulating the angiogenic process, as they are administered orally they present a better 
patient treatment compliance (310). Sunitinib is an orally active antagonist of VEGFR-1, PDGFR and 
c-Kit, received FDA approval in 2006 for treatment of renal cell advanced carcinoma and 
Gastrointestinal stroma tumours resistant to imatinib (310) and Vandetanib is an orally active 
antagonist of VEGFR-2, epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, 
and is available for the treatment of metastatic medullary thyroid cancer (275). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
__________________________________________________________________2.  AIMS 
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 CRC is a major public health problem; on the one hand it presents a high incidence and 
prevalence, on the other hand the elevated cost associated with diagnostic and treatment measures. 
Despite recent advances in both, earlier diagnosis and treatment options, that resulted in a reduction 
of CRC mortality, this remains considerably.  
Nowadays research in CRC has turned to the attempt to identify new biological markers that 
can be used as potential therapeutic targets that selectively operate in cancers cells and that along 
with TNM staging system, can be used to identify subgroups of patients that will have a worse 
prognostic and so offer those more aggressive therapeutics and follow-up measures. The 
assessment of metabolic and angiogenic markers fulfil these two goals, so with this work we intend 
to identify the prevalence of selected Metabolic and Angiogenenic markers of Colorectal Cancer and 
determine possible associations with clinicopathological characteristics and impact on prognosis by: 
 
- Elaborating a clinicopathological data base of patients with CRC diagnosis treated at Braga 
Hospital between 1 January 2005 and 1 January 2010.  
 
- Evaluating the role of MCTs in the carcinogenesis of CRC by assessing the 
immunohistochemical expression of the MCT isoforms 1 and 4, chaperones CD147 and 
CD44 and glycolytic metabolic marker GLUT1. 
 
- Investigating the role of VEGF family in the carcinogenesis of CRC by assessing the 
immunohistochemical expression of VEGF-A, VEGF-B, VEGFR-2 and VEGFR-3. 
- Correlating the expression of the protein markers with clinicopathological parameters.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______________________________________________3. MATERIALS AND METHODS 
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The beginning of the development of this thesis coincided with the creation of the 
Coloproctology Unit of Braga Hospital, responsible, among others diseases, by the treatment of 
patients with diagnosis of colorectal cancer.       
 In order to standardize the diagnosis, staging, treatment and follow-up of these patients we 
have elaborated several protocols that were discussed with the Oncology team and approved by the 
“Conselho de Administração of Braga Hospital”.  (approved protocols are in appendix 1-8:“Protocolo 
de estudo de Cancro do Colon”; “Protocolo de estudo de Cancro do Recto”; “Protocolo de Registo 
de Cancro Colorectal”; “Protocolo Terapêutico de Cancro Recto”; “Protocolo de Follow-up de Cancro 
Colorectal”; “Protocolo de Registo de recidiva de Cancro Colorectal”; “Protocolo de Antibioprofilaxia 
para Cirurgia Colorectal” and “Protocolo de Processamento da peça operatória”). 
 Most patients (except emergent cases) were discussed preoperatively by a multidisciplinary 
team involving surgeons, oncologists and sometimes a pathologist.  
 
 
3.1 EPIDEMIOLOGICAL DATA 
 
We conducted an observational, prospective and descriptive study between 1 January 2005 
and 1 January 2010. The population covered consisted in all patients with histological CRC 
diagnosis, treated at Braga Hospital.                          
 Data from 672 patients, with CRC diagnosis, were collected prospectively in two excel 
databases – Colon Cancer and Rectal Cancer – data regarding clinical, preoperative diagnostic 
examinations, operative reports by the surgeons, histopathological and follow-up were collected.  
 Clinical and preoperative diagnostic examinations included: age, gender, past oncologic 
history, clinical presentation, tumour localization, tumour mobility (for rectal cancer), histological 
type, macroscopic appearance, carcinoembryonic antigen (CEA) level and preoperative staging.  
 Tumour localization was recorded and classified as right sided (caecum, ascending colon, 
hepatic flexure and transverse colon), left sided (splenic flexure, descending colon, sigmoid colon) 
and rectum (between anal verge and 15 cm at rigid rectoscopy). Rectal cancer localization was 
subdivided as superior, middle and lower third (≤15 and > 10 cm; ≤10 and > 5 cm and ≤ 5cm from 
anal verge, respectively). Except for emergent cases (defined as a surgery performed for obstruction  
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
_________________________________________________________________________
42 
 
 
or perforation of the colon or rectum) all patients were preoperatively staged for local and distant 
metastases by chest x-ray and abdominal CT in colon cancer, and toraco-abdominal CT, pelvic 
magnetic resonance and rectal ultrasonography in rectal cancer.    
 Operative reports by surgeons like presence of perforation, tumour mobility and type of 
surgery were also collected. All patients received antibiotic and thrombosis prophylaxis and all 
operations were performed by or under supervision of a senior surgeon.   
 The histopathological reports included: tumour extent (T), extent of spread to lymph nodes 
(N), presence of distant metastasis (M), tumour differentiation, resection margin involvement and 
lymphatic and blood vessel invasion. The level of positive lymph nodes was not described in all 
specimens. The histological type of CRC was determined by two experienced pathologists and 
tumour staging was graded according to TNM classification, sixth edition (311).   
 All patients were followed up periodically, and their outcomes were investigated. 
 All cases in this study were identified using a series of unified Code and the study protocol 
was approved by the Ethics Committee of Braga Hospital. All patients provided written consent. 
 
 
3.2 TUMOUR BLOCK SELECTION  
 
At Pathology Department of Braga Hospital, we proceeded to the selection of the surgical 
specimens blocks of the patients submitted to colorectal cancer resection, ideally with “tumour” and 
“normal adjacent epithelium” in the same block. This block selection was confirmed by a pathologist 
and corresponded to 580 cases of the 672 patients with CRC diagnosis, since there were patients 
who did not undergo surgical intervention, patients that have been operated in other institutions and 
patients for who was not possible to retrieve the paraffin block. Another series of 45 patients with 
histological diagnosis of CRC Hepatic Metastasis operated between 1 January 2003 and 1 de 
January 2011 was also collected.  
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3.3 HEMATOXYLIN-EOSIN STAINING SLIDES PREPARATION 
 
After tumour block selection, Hematoxylin-eosin (HE) slides of all cases, CRC and Hepatic 
metastasis, were made at “Life and Health Sciences Research Institute” (ICVS) laboratory. In all this 
slides we proceed to the selection of “tumour” and “normal adjacent epithelium” in both series. This 
selection was confirmed by a pathologist.  
 
 
3.4 CONSTRUCTION OF TISSUE MICROARRAYS 
 
In CRC series, after identification, in HE slides, of “tumour” and “normal adjacent 
epithelium”, new slides with 80 cases of “tumour” and “normal adjacent epithelium” were made at 
ICVS laboratory. In the Tissue Microarray (TMAs) technique, a hollow needle is used to remove 
tissue cores as small as 0.6 mm in diameter from regions of interest in paraffin-embedded tissues. 
These tissue cores are then inserted in a recipient paraffin block in a precisely spaced, array pattern. 
Sections from this block are cut using a microtome, mounted on a microscope slide.   
 
 
3.5 IMMUNOHISTOCHEMISTRY  
 
In CRC series, TMA protein expression of metabolic markers (MCT1, MCT4, CD147, CD44 
and GLUT1) and angiogenic markers (VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3) was evaluated by 
immunohistochemistry.          
 In Colorectal cancer Hepatic Metastasis series, protein expression of metabolic markers 
(MCT4, CD147, CD44 and GLUT1) was evaluated by immunohistochemistry. MCT1 
immunohistochemical reaction was not performed, in this series, due to problems with the 
“detection system”. 
 Detailed information is given in Table III and IV. Briefly, after deparaffinization and 
rehydration, 4µm cytoblock sections were immersed in 0.01M citrate buffer (pH 6.0) and heated at 
98 ºC for 20 minutes for epitope antigen retrieval. Subsequently, endogenous peroxidase was  
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blocked with 0.3% hydrogen peroxide in methanol. Slides were then incubated with the respective 
primary antibodies and 3,3’-diamino-benzidine (DAB+ Substrate  System, Dako) was used for 
detection. Cytoblock sections were counterstained with haematoxylin and permanently mounted. 
Negative controls were obtained by omitting the primary antibody incubation step.  
After immunohistochemical procedure, the slides were evaluated.  
 
 
Table III: Detailed aspects of the immunohistochemical procedure used to visualize the different metabolic proteins.                            
 
 
Protein 
Marker 
 
Antigen 
retrieval 
 
Positive 
Control 
 
Peroxidase 
inactivation 
 
Detection 
system 
 
Antibody 
 
  
   Company Dilution 
Incubation 
period 
 
 
MCT1 
 
 
Citrate buffer 
10mM 
pH=6.0 
 
 
 
Colon 
carcinoma 
 
 
0.3% H2O2 in 
methanol, 
30 min. 
 
R.T.U. 
VECTORSTAIN
® Elite® ABC 
Kit 
 
 
 
CHEMICON 
 
 
 
1:300 
 
 
 
Overnight 
 
 
MCT4 
 
Citrate buffer 
10mM 
pH=6.0 
 
 
Colon 
carcinoma 
 
0.3% H2O2 in 
methanol, 
30 min. 
 
R.T.U. 
VECTORSTAIN
® Elite® ABC 
Kit 
 
 
Santa Cruz 
Biotechnology 
 
 
1:200 
 
 
 
Overnight 
 
 
 
 CD147 
 
EDTA 
1mM 
pH=8 
 
 
Colon 
carcinoma 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
 
Zymed 
 
 
1:500 
 
 
2 hours 
 
 
 CD44 
 
Citrate buffer 
10mM 
pH=6.0 
 
 
 
Duodenum 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
 
Serotec 
 
 
1:400 
 
 
2 hours 
 
 
 GLUT-1 
 
Citrate buffer 
10mM 
pH=6.0 
 
 
 
 
Skin 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
 
Abcam  
 
 
1:500 
 
 
2 hours 
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Table IV: Detailed aspects of the immunohistochemical procedure used to visualize the different angiogenic proteins. 
 
 
 
Protein 
Marker 
 
Antigen 
retrieval 
 
Positive 
Control 
 
Peroxidase 
inactivation 
 
Detection system 
 
Antibody 
 
  
  
    
Company 
 
Dilution 
 
Incubation 
period 
 
VEGF-A 
 
EDTA Buffer 1X  
pH=8.0 
 
Tonsil 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
Abcam 
 
1:100 
 
Overnight 
 
VEGF-C 
 
EDTA Buffer 1X  
pH=8.0 
 
Tonsil 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
Invitrogen 
 
 1:200 
 
Overnight  
 
VEGFR-2 
 
Citrate Buffer 
0.01M  pH=6.0 
 
Tonsil 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
Abcam 
 
1:100 
 
Overnight 
 
VEGFR-3 
 
Citrate Buffer 
0.01M  pH=6.0 
 
Tonsil 
 
3% H2O2 in 
methanol, 
10 min. 
 
LabVision 
 
Abcam 
 
1:100 
 
Overnight 
 
 
3.6  IMMUNOHISTOCHEMICAL EVALUATION  
Sections were evaluated for immunoreaction, which included both cytoplasmic and 
membrane-positive staining. MCT1, MCT4, CD147, CD44, GLUT, VEGF-A, VEGF-B, VEGFR-2 and 
VEGFR-3 immunohistochemical reactions were scored semi-quantitatively for immunoreaction 
extension as follows (Table V): 0: 0% of immunoreactive cells; 1: <5% of immunoreactive cells; 2: 
5–50% of immunoreactive cells; and 3: >50% of immunoreactive cells. Also, intensity of staining was 
scored semi-qualitatively as 0: negative; 1: weak; 2: moderate; and 3: strong. Immunoreaction final 
score was defined as the sum of both parameters (extension and intensity), and grouped as negative 
(0), weak (2), moderate (3), and strong (4–6). For statistical purposes, only moderate and strong 
immunoreaction final scores were considered as positive. Positive plasma membrane staining was 
also assessed. Immunohistochemical expression evaluation was performed blindly by two 
independent observers and discordant cases were discussed in order to determine a final score. 
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Table V: Criteria for evaluation immunoreaction depth and the intensity staining. 
 
Extension Intensity 
Scored Immunoreactive 
cells (%) 
Scored Staining 
    
0 0% 0 Negative 
1 <5% 1 Weak 
2 5 a 50% 2 Moderate 
3 >50% 3 Strong 
 
 
 
3.7 STATISTICAL ANALYSIS 
 
All data were collected and stored in an Excel PC database and statistically analyzed using 
the Statistical Package for the Social Sciences, version 19.0 (SPSS Inc., Chicago, Illinois, USA). All 
comparisons were examined for statistical significance using Pearson’s chi-square (χ2) test and 
Fisher’s exact test (when n < 5), with the threshold for significance P values <0.05.  
Overall survival (OS) was defined as time from disease diagnosis until death from any cause 
and Survival free disease (DFS) was defined as time from disease diagnosis until disease relapse, 
both were assessed using the Kaplan-Meier method. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_______________________________________________________________ 4. RESULTS 
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4.1EPIDEMIOLOGICAL  CHARACTERIZATION 
 
  Data from 672 patients treated between 1 January 2005 and 1 January 2010 at Braga 
Hospital, with CRC diagnosis was collected prospectively in two excel databases – Colon Cancer and 
Rectal Cancer. Clinical, preoperative diagnostic examinations, operative reports by the surgeons, 
histopathological and follow-up data were collected.  
 
4.1.1 GENERAL CHARACTERIZATION 
4.1.1.1 AGE AND GENDER    
 
 The casuistic included 672 patients, 419 (62.4%) males and 253 (37.6%) females; the age 
range of most patients (61%) was 61-80 years old, 20.4% (n=137) 41-60 years old; 16.1% (n=108) 
older than 81 and 2.5% (n=17) younger than 40 years old (Figure 10). Except for the group older 
than 81 years old, CRC incidence was more frequent in men.  
2,5%
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Figure 10: Age distribution of CRC patients. 
 
 
4.1.1.2 ANATOMIC DISTRIBUTION OF TUMOURS  
 
 Among the 672 patients, 439 tumours (65.3%) arouse from colon and 233 (34.7%) from 
rectum (Figure 11). 
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Figure 11: Anatomic distribution of CRC.  
 
4.1.1.3 PAST PERSONAL AND FAMILIAR HISTORY   
 
In patients with colon and rectum cancer, n=672, analysis of past personal history of 
presence of polyps, colorectal or other cancers and familiar CRC history showed that 94.8% (n=637) 
of patients had no history of previous colorectal polyps; from the patients with polyps, 4.3% (n=29) 
were tubular, 0.4% (n=3) adenomatosos, 0.3% (n=2) tubulo-viloso and 1 was non-classified.  
 From overall patients, 4.1% (n= 28) had previous personal history of CRC and 7.7 % (n=52) 
had personal history of other cancer. 9.7% (n=65) had a positive CRC familial story.  
 
4.1.1.4 CLINICAL PRESENTATION  
 
 Most of patients, 81.3 % (n=546), with CRC were symptomatic at diagnosis, the remainder 
18.8% (n=126) were asymptomatic and detected by routine colonoscopies (Figure 12). From the 
symptomatic patients, 82.1% (n= 450) of patients presented symptoms 6 months prior to 
colonoscopy and 14.6% (n=98) symptoms beyond 6 months. 
 
546 
(81,3%)
126 
(18,8%)
symptomatic
asymptomatic
 
Figure 12: CRC presentation at diagnosis. 
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4.1.2 COLON CANCER  
4.1.2.1 CLINICAL AND PREOPERATIVE DIAGNOSTIC AND STAGING EXAMINATION 
4.1.2.1.1 CLINICAL PRESENTATION  
 
 Most colon cancer patients (77.4%, n=340 patients), were symptomatic at diagnosis. The 
most frequent symptom was digestive bleeding, 17.1% (n= 75), followed by large bowel obstruction, 
15% (n= 66). Other frequent symptoms observed were: change in bowel habits (8.9%), change in 
bowel habits with digestive bleeding (8.6%), constitutional symptoms (6.6%), change in bowel habits 
with abdominal pain (6.4%) and abdominal pain (4.8%) (Table VI). 
 
 
Table VI: Summary of colon cancer symptoms.    
 
Symptom n (%) 
Digestive bleeding 75 (17.1) 
Large bowel obstruction 66 (15.0) 
Change in bowel habit 39 (8.9) 
Digestive bleeding + changes in bowel habit 38 (8.6) 
Constitutional symptoms 29 (6.6) 
Abdominal pain +  changes in bowel habit 28 (6.4) 
Study (ascites; anemia, deep venous thrombosis, hepatic metastasis; 
occult blood losses, colonvesical fistula) 
23 (5.2) 
Abdominal pain 21 (4.8) 
Parcial large bowel obstruction 13 (3.0) 
Large bowel perfuration 8 (1.8) 
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4.1.2.1.2 LOCALIZATION  
 
Most cancers were left-colon, 64.7% (n=284): 6.8% (n=30) were in the splenic flexure; 4.3% 
(n=19) in the descending colon, 49.2% (n=216) in the sigmoid colon, and 4.3% (n=19) in the 
rectosigmoid transition. Right-sided tumours comprised 35.3% (n=155) of patients: 8.4 % (n=37) 
were localized in the caecum, 8.2% (n=36) in the ascending colon and 13.7% (n=60) in the hepatic 
flexure. 5.0% (n=22) of cancers were localized in the transverse colon.  
  
4.1.2.1.3 DIAGNOSIS AND STAGING 
 
Imaging diagnosis was made by total colonoscopy in 76.1% (n=334) of cases and 
rectosigmoidoscopy in 13% (n=57). In 10.9% (n=48), diagnosis was made by other imagiological 
exams and patients did not have a preoperative colonoscopy. 
Most lesions (47.2 %, n=207) were polypoid/vegetant cancers. The remaining 21.0% (n=92) 
were ulcerated, 8.4% (n=37) infiltrative and 11.2% (n=49) exofitic cancers (Figure 13). In 54 
patients (12.3%) there was no cancer macroscopic appearance information. In 19.1% (n=84) of 
patients, synchronous lesions were observed.  
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Figure 13: Frequency of macroscopic colon cancer appearance. 
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Pre-operative colon biopsy revealed colon adenocarcinoma in 83.8% (n=368) of the patients, 
3.9% (n=17) there was no preoperatory information. 85.7% (n=376) of patients were staged by 
computerized axial tomography and most patients (79.1%; n=347) with colon cancer had a localized 
cancer at diagnosis. Most patients with disseminated disease had hepatic metastasis, followed by 
lymph node metastasis (Table VII).  
 
 
Table VII: Summary of colon cancer metastasis localization.  
 
Metastasis n (%) 
Lymph node 24 (5.5) 
Lymph node + Hepatic  7 (1.6) 
Lymph node + Hepatic + pulmonary 3 (0. 7) 
Hepatic 44 (10.0) 
Hepatic + pulmonary 4 (0.9) 
Hepatic + pulmonary + bone 3 (0.7) 
Hepatic +spleen+ bone 1 (0.2) 
Pulmonary 3 (0.7) 
Peritoneal 3 (0.7) 
 
 
 4.1.2.2 OPERATIVE REPORTS BY SURGEONS 
 
Of the 439 patients with colon cancer diagnosis, 422 (96.1%) were submitted to surgical 
treatment in this period; 334 (79.1%) and 88 (20.9%) were submitted to a scheduled and urgent 
surgery, respectively. At exploration, 32 patients (7.6%) presented tumour perforation, including not 
only the patients with clinical perforation, but also the patients with buffered tumour perforation and 
iatrogenic perforation during surgery.  
Also at surgical exploration, 347 (82.2%) had a mobile tumour, 65 (17.8%) a fixed tumour 
and no information was available for 10 patients. 
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 4.1.2.3 HISTOPATHOLOGICAL REPORTS 
 
Histopathological reports were determined by two experienced pathologists at the 
Pathology Department of Braga Hospital. 
 
 4.1.2.3.1 TUMOUR SIZE     
 
Most patients, 207 patients (49.0%), presented with tumours smaller than or equal to 4.5 
cm, 165 (39.0%) patients presented with tumour bigger than 4.5 cm and in the remainder no size 
information was referred. 
 
4.1.2.3.2 MACROSCOPIC SEROSAL INVOLVEMENT     
 
Macroscopic serosal involvement was observed in 295 patients (69.9%). In 103 (24.4%) 
this was not observed and not referred in the remainder 24 patients. 
 
4.1.2.3.3 TUMOUR DIFFERENTIATION   
 
 Most patients, 172 (40.8%), presented a moderately-differentiated tumour, followed by well 
and poorly-diferentiated tumour (168 and 41 patients, respectively). 1 patient presented an 
undifferentiated tumour (Figure 14).  
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Figure 14: Distribuition of colon cancer differentiation. 
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 4.1.2.3.4 RESSECTION MARGINS INVOLVEMENT  
 
 Ressection Margins examination did not reveal involvement in 392 patients, this was 
observed in 6 patients and in the remainder 24 this was not mentioned. 
 
 4.1.2.3.5 VASCULAR INVASION    
 
Although no specific marker of lymphatic or hematogeneous vessels was been used, it was 
documented that 229 (54.2%) patients had venous vessel invasion and 166 (39.3%) lymphatic 
vessel invasion. In 156 (36.9%) and 209 (49.5%) patients, respectively, no invasion was documented 
and in the remainder there was no information. 
 
4.1.2.3.6 HISTOLOGICAL STAGING 
 
Histological staging was determined by two experienced pathologists and tumour staging 
was graded according to the TNM classification, sixth edition (American Joint Commitence on 
Cancer) (311). In the majority of patients (33.7%; n=142) colon cancer was stage IIA, followed by 
stage IIIB (22.5%; n=95). In 7 patients post-operative histological stage was not determined because 
the patients underwent surgery without resection (ex. derivative colostomy) (Table VIII).  
 
4.1.2.4 FOLLOW-UP         
   
A total of 137 patients (31.2%) died from all causes, 27.8% (122 patients) had a colorectal 
cancer-related cause and the remaining 3.4% (15 patients) died in the post-operative period 
(mortality within 30 days of surgery). Follow-up time ranged between 2 and 7 years; 14.6% (62 
patients) had recurrence during follow-up. Stage IIIB was the stage most frequently associated            
with tumour recurrence (Table IX).  
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Table VIII: Summary of colon cancer histological staging. 
 
Stage n (%) 
0 9 (2.1) 
I 55 (13.0) 
IIA 142 (33.7) 
IIB 11 (2.6) 
IIIA 6 (1.4) 
IIIB 95 (22.5) 
IIIC 18 (4.3) 
IV 79 (18.7) 
 
 
 
 
Table IX: Summary of histopathogical tumour staging of colon cancer recurrence. 
 
Stage n (%) 
I 1 (1.6) 
IIA 12 (19.4) 
IIB 6 (9.7) 
IIIA 1 (1.6) 
IIIB 22 (35.4) 
IIIC 4 (6.5) 
IV 16 (25.8) 
 
 
 
Most metastasis occurred in liver, followed by lymph node and lung. Local recurrence 
occurred in nine cases (Table X).        
 Most patients wih metastasis and recurrence were asymptomatic (79.0%; n=49), of that 
29.0% (n=18) of patients presented asymptomatic elevation of tumour markers. The remaining  
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cases were patients with abdominal pain (4.8%; n=3), abdominal mass (4.8%; n=3), intestinal 
obstruction (3.2%; n=2), bone pain (3.2%; n=2), supraclavicular mass (1.6%; n=1), enterocutaneous 
fistula (1.6%; n=1) and pathological fracture (1.6%; n=1) (Table XI). 
 
Table X: Summary of colon cancer metastasis localization and recurrence. 
 
Metastasis localization and Recurrence n (%) 
Hepatic 32 (51.6) 
Local recurrence* 9 (14.5) 
Lymph node 5 (8.1) 
Pulmonary 5 (8.1) 
Peritoneal carcinomatosis 4 (6.5) 
Hepatic + Pulmonary 3 (4.8) 
Hepatic + Pulmonar + Peritoneal carcinomatosis 1 (1.6) 
Hepatic + adrenal glands 1 (1.6) 
Hepatic + Peritoneal carcinomatosis 1 (1.6) 
Bone 1 (1.6) 
*Local recurrence refers to anastomotic, para-anastomotic and abdominal mass 
 
 
Table XI: Summary of symptoms/signs in colon cancer metastasis and recurrence. 
 
Metastasis and Recurrence Colon Cancer 
symptoms/signs 
n (%) 
Abdominal mass 3 (4.8) 
Abdominal pain 3 (4.8) 
Intestinal obstruction 2 (3.2) 
Bone pain 2 (3.2) 
Supraclavicular mass 1 (1.6) 
Pathological fracture 1 (1.6) 
Enterocutaneous fistula 1 (1.6) 
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 4.1.3 RECTAL CANCER  
 4.1.3.1 CLINICAL AND PREOPERATIVE DIAGNOSTIC AND STAGING EXAMINATION       
      4.1.3.1.1 CLINICAL PRESENTATION  
  
 Most rectal cancer patients (88.5%, n=206 patients), were symptomatic at diagnosis. 23% 
(n= 54) presented digestive bleeding, followed by digestive bleeding with change in bowel habits, 
17.4% (n= 41). Other frequent symptoms observed were: change in bowel habits (14.5%; n= 34) 
and large bowel obstruction (4.7%; n= 11) (Table XII).  
 
Table XII: Summary of rectal cancer symptoms.   
 
Symptom n (%) 
Digestive bleeding 54 (23.0) 
Digestive bleeding + change in bowel habit 41 (17.4) 
Change in bowel habit 34 (14.5) 
Large bowel obstruction 11 (4.7) 
Incomplete stool evacuation sensation 11 (4.7) 
Tenesmus 10 (4.2) 
Tenesmus + Digestive bleeding 10 (4.2) 
Tenesmus +  changes in bowel habit 9 (3.8) 
Abdominal pain 7 (3.0) 
Constitutional symptoms 6 (2.6) 
Abdominal pain + digestive bleeding 5 (2.1) 
Study (hepatic metastasis, pelvic mass) 4 (1.7) 
Large bowel perfuration 2 (0.9) 
Urgency 1 (0.4) 
Anal pain 1 (0.4) 
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4.1.3.1.2 LOCALIZATION 
 
From the 233 rectal cancers, most (50.6%, n=118) were localized in the middle third, 
followed by distal rectum in 28.3% (n=66) and proximal rectum in 21% (n=49).  
  
4.1.3.1.3 DIAGNOSIS AND STAGING   
           
 In rectal cancer patients, diagnosis was made by total colonoscopy in 79.8% (n=186) and 
rectosigmoidoscopy in 18.9% (n=44). In 1.3% (n=3) of cases, it was impossible to perform an 
endoscopic exam (rectal stenosis). 
Most lesions (55.8%, n=130) were polypoid/vegetant cancers. The remaining 21.0% (n=49) 
were ulcerated, 10.7% (n=25) were infiltrative; 9.0% (n=21) exofitic cancers; 0.4% (n=1) were 
vilosous and for the reminder 7 patients (3%) there was no cancer macroscopic appearance 
information (Figure 15). Synchronous lesions were observed in 10.3% (n=24) of patients. 
 
55.8%
21%
10.7% 9%
0%
10%
20%
30%
40%
50%
60%
Polypoid/vegetant Ulcerated Infiltrative Exofitic
 
 
Figure 15: Frequency of macroscopic rectal cancer appearance.  
 
Pre-operative biopsy revealed rectal adenocarcinoma in 91.4% (n=213) of the patients, 
invasive adenocarcinoma in 2.1% (n=5), adenomatosous dysplasic lesions in 4.7% (n=11); villous 
lesions in 1.3% (n=3) and mucinous adenocarcinoma in one patient (0.4%). From the 233 patients, 
27.0% (n=63) had synchronic metastasis at diagnosis, more frequently lymph node and hepatic 
metastasis (Table XIII).  
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Table XIII: Summary of rectal cancer metastasis localization.    
 
Metastasis n (%) 
Lymph node 24 (10.2) 
Hepatic 20 (8.5) 
Peritoneal 6 (2.6) 
Pulmonary 4 (1.7) 
Lymph node + Hepatic + pulmonary 4 (1.7) 
Lymph node + pulmonary 2 (0.8) 
Hepatic + pulmonary 1 (0.4) 
Hepatic + pulmonary + adrenal 1 (0.4) 
Bone 1 (0.4) 
 
 
 Pelvic magnetic resonance (MR) and rectal endoscopic ultrasound (EUS) were used in 
combination for local staging. After staging, 26% (61 patients) had indication for neoadjuvant 
therapy; 21% (49 patients) underwent chemotherapy and radiotherapy, the remaining had not done 
neoadjuvant therapy due to comorbidities (2 patients) or underwent chemotherapy or radiotherapy 
alone due to specific contra-indications (Table XIV).  
 
 
Table XIV: Summary of neoadjuvant treatment.    
 
Neoadjuvant Treatment n (%) 
None 172 (73.8) 
With indication for neoadjuvant treatment but comorbilities 2 (0.9) 
Neoadjuvant chemotherapy and radiotherapy 49 (21.0) 
Neoadjuvant chemotherapy 8 (3.4) 
Neoadjuvant radiotherapy 2 (0.9) 
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 4.1.3.2 OPERATIVE REPORTS BY SURGEONS    
 
 
From the 233 patients with rectal cancer diagnosis, 203 (87.1%) were submitted to surgical 
treatment in this period; 193 (95.1%) and 10 (4.9%) were submitted to a scheduled and urgent 
surgery, respectively. At exploration, 3 patients (1.5%) presented tumour perforation, including not 
only the patients with clinical perforation, but also the patients with buffered tumour perforation and 
iatrogenic tumour perforation during surgery. In 197 (97.0%) patients no perforation was 
documented and in 3 patients this data was not referred.  
At surgery, mobility exploration was documented in 136 (66.9%) patients, 50 (24.6%) 
patients had a fixed tumour and in 17 patients this data was not referred. 
 
4.1.3.3 HISTOPATHOLOGICAL REPORTS 
 4.1.3.3.1 TUMOUR SIZE     
 
Most patients, 107 patients (52.7%), presented tumours smaller than or equal to 4.5 cm, 
48 (23.6%) patients presented tumours bigger than 4.5 cm and in the remainder 48 patients no size 
information was referred. 
 
 4.1.3.3.2 MACROSCOPIC SEROSAL INVOLVEMENT   
 
From the patients examinated, 109 (53.7%) presented macroscopic serosal involvement and 
70 (34.5%) without. No information was referred in the remainder 24 patients. 
 
 4.1.3.3.3 TUMOUR DIFFERENTIATION    
   
Most patients, 80 (39.4%) presented a moderately-differentiated tumours, followed by well 
and poorly-diferentiated tumours (73 (36.0%) and 9 (4.4%) patients, respectively). 1.0% of patients (2 
patients) presented undifferentiated tumours and in 40 patients this data was not mentioned 
(Figure 16).  
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Figure 16: Distribution of rectal cancer differentiation. 
 
 
4.1.3.3.4 RESSECTION MARGIN INVOLVEMENT  
 
Ressection Margins examination did not reveal involvement in 155 patients (76.4%), this 
was observed in 20 patients (9.6%) and for the remainder 28 this data was not mentioned. 
 
 4.1.3.3.5 VASCULAR INVASION 
 
As previously mentioned, despite no specific marker of lymphatic or hematogeneous vessels 
being used, it was documented that 113 (55.6%) patients had venous vessel invasion and 90 
(44.3%) lymphatic vessel invasion. In 59 (29.0%) and 81 (39.9%), respectively, no invasion was 
documented and for the remainder patients no information was mentioned. 
 
4.1.3.3.6 HISTOLOGICAL STAGING  
 
 Post-operative histological staging was determined by two experienced pathologists and 
tumour staging was graded according to the TNM classification, sixth edition (American Joint 
Commitence on Cancer) (311). Most patients with rectal cancer were stage IIA (21.2%) and stage I 
(18.7%), followed by stage IV (18.2% patients). In 8 patients, post-operative histological stage was 
not determined because the patients have realized surgery without resection (ex. derivative 
colostomy) (Table XV).  
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Table XV: Summary of rectal cancer histopathological staging. 
 
Stage n (%) 
0 21 (10.3) 
I 38 (18.7) 
IIA 43 (21.2) 
IIIA 12 (5.9) 
IIIB 31 (15.3) 
IIIC 13 (6.4) 
IV 37 (18.2) 
 
4.1.3.4 FOLLOW-UP   
           
 A total of 52 patients (22.3%) died from all causes, 28.0% (42 patients) had a colorectal 
cancer-related cause and the remaining 4.3% (10 patients) died in the post-operative period 
(mortality within 30 days of surgery).Follow-up time ranged from 2 to 7 years; 18.0% (42 patients) 
had recurrence during follow-up. Stage IV was the stage most often associated with tumour 
recurrence (Table XVI).  
 
 
Table XVI: Summary of histopathological tumour staging of rectal cancer recurrence. 
 
Stage n (%) 
I 4 (9.5) 
IIA 12 (28.6) 
IIIB 7 (16.7) 
IIIC 3 (7.1) 
IV 16 (38.1) 
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Most metastasis occurred in liver, followed by lung, while local recurrence occurred in 9 
patients (Table XVII). Most patients with metastasis and recurrence (73.8%; n=31) were 
asymptomatic and 14.2% (n=6) of those presented with asymptomatic elevation of tumour markers. 
In the case of symptomatic patients, the most frequent symptoms/signs was a rectal mass (9.5%; 
n=4), and intestinal obstruction 4.7% (n=2) (Table XVIII). 
 
 
Table XVII: Summary of rectal cancer metastasis localization and recurrence. 
 
Metastasis localization and Recurrence n (%) 
Hepatic 17 (40.5) 
Local recurrence 9 (21.3) 
Pulmonary 5 (11.9) 
Hepatic + Pulmonary 4 (9.5) 
Carcinomatosis 1 (2.4) 
Bone 1 (2.4) 
Hepatic + Pulmonar  + adrenal glands 1 (2.4) 
Hepatic + Pulmonary + Bone 1 (2.4) 
Hepatic + Pulmonary + Lymph node 1 (2.4) 
Pulmonar and Bone 1 (2.4) 
Hepatic + Lymph node 1 (2.4) 
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Table XVIII: Summary of symptoms/signs in rectal cancer metastasis and recurrence. 
 
Metastasis and Recurrence Rectal Cancer 
symptoms/signs 
n (%) 
Rectal mass 4 (9.5) 
Intestinal obstruction 2 (4.7) 
Bone pain 1 (2.4) 
Metrorrhagia 1 (2.4) 
Anal pain 1 (2.4) 
Pleural effusion 1 (2.4) 
Rectal blood loss 1 (2.4) 
 
 
 
4.1.4 COLORECTAL CANCER OVERALL SURVIVAL   
 
 Overall survival (OS) was defined as the time from disease diagnosis until death from any 
cause and Survival free disease (DFS) was defined as the time from disease diagnosis until disease 
relapse, both were assessed using the Kaplan-Meier method (Figure 17 and 18). When patients 
were divided into two groups by location, colon and rectum, no significant difference was found in 
the survival rate between the colon cancer group and rectal cancer group; assessed by log-rank test 
(Figure 19). 
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Figure 17: Kaplan-Meier curve depicting overall survival 
CRC curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Kaplan-Meier curve depicting disease-free 
survival CRC curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Comparison between colon and rectum cancer 
survival assessed by log-rank test. 
 
p =0.518 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
_________________________________________________________________________
67 
 
 
 
4.2 ANALYSIS OF THE ASSOCIATIONS OF MCTS, CHAPERONES AND GLYCOLYTIC 
METABOLIC MARKERS IN PRIMARY COLORECTAL CANCERS AND NORMAL ADJACENT TISSUES 
 
Our previous study analyzed the expressions of MCT1, 2, and 4 in a series of 126 CRC 
(109) and we reported that the expression of the MCT isoforms in tumour cells was significantly 
increased when compared to normal adjacent epithelium. Remarkably, there was a significant gain 
in membrane expression for MCT1 and MCT4 and loss of plasma membrane expression for MCT2 
in tumour cells. However, the tumour series analyzed at that time was relatively small. To reinforce 
the results obtained, we evaluated MCT1, MCT4 immunohistochemical expression in this series of 
580 cases, adding evaluation of immunohistochemical expression of the MCT chaperones CD147, 
CD44 and the glycolytic metabolic marker GLUT1, besides the advantage of the possibility of 
correlation with epidemiological patients’ data. Sections were evaluated for immunoreaction, which 
included both cytoplasmic and membrane-positive staining. 
 
 
4.2.1 MCT1, MCT4, CD147, CD44 AND GLUT1 IMMUNOHISTOCHEMICAL 
EXPRESSION IN CRCS AND NORMAL ADJACENT TISSUES 
 
The results obtained are described in Table XIX, which summarizes the frequency of MCT 
isoforms 1 and 4, chaperones CD147 and CD44 and glycolytic metabolic marker GLUT1 
expressions, in tumour and normal adjacent (NA) epithelium. 
 
Figure 20 shows representative cases of MCT1, MCT4, CD147, CD44 and GLUT1 positive 
staining in tumour cells and in normal adjacent epithelium. 
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Table XIX: Pattern of protein staining in CRC vs. normal adjacent epithelium. 
 
Protein 
 
Immunoreaction Plasma membrane 
 n Positive (%) p Positive (%) p 
MCT1   <0.001  <0.001 
           NA 
           Tumour 
135 
501 
106 (78.5%) 
469 (93.6%) 
 104 (77.0%) 
464 (92.6%) 
 
MCT4   <0.001  <0.001 
            NA 
           Tumour 
108 
484 
42 (38.9%) 
368 (76.0%) 
 6 (5.6%) 
275 (56.8%) 
 
CD147   <0.001  <0.001 
            NA 
           Tumour 
139 
495 
19 (13.7%) 
179 (36.2%) 
 17 (12.2%) 
162 (32.7%) 
 
CD44   <0.001  <0.001 
            NA 
           Tumour 
103 
486 
1 (1.0%) 
138 (28.4%) 
 1 (1.0%) 
123 (25.3%) 
 
GLUT1   <0.001  <0.001 
            NA 
           Tumour 
108 
464 
7 (6.5%) 
156 (33.6%) 
 4 (3.7%) 
132 (28.4%) 
 
 
 
Analyzing the results of Table XIX, it is possible to observe that all the proteins studied are 
overexpressed in tumours when comparing with normal-adjacent tissue and in plasma membrane 
expression pattern (p<0.001). We detect a significant increase in both MCT1 and MCT4 expressions 
when comparing normal adjacent epithelium to tumour tissues (p < 0.001, for both), corresponding 
to 93.6% and 76.0%, respectively and similar results were observed when analyzing membrane 
expression. Percentage of positive cases decreased for the chaperones CD147 and CD44 as well as 
in the glycolytic metabolic marker GLUT1. 
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Figure 20: MCT1, MCT4, CD147, CD44 and GLUT1 immunohistochemical expression in CRC samples  
                   (200x magnification). 
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4.2.2 EVALUATION OF ASSOCIATIONS BETWEEN MCTS, CD147, CD44 AND GLUT1 
EXPRESSION IN CRC  
 
Functional expression of MCTs is regulated by accessory proteins, such as CD147, that are 
involved in trafficking and anchoring of plasma membrane proteins (135). Regulation of MCT1 and 
MCT4 by CD147, was supported by evidence on human and in vitro studies (104,135,157–161). 
CD44 is a transmembrane glycoprotein that plays an important role in communication of cell-matrix 
interactions (181,182) and also function as a chaperone for MCT expression (162).  
Moreover, as a consequence of high energetic demands, CRC cells show an increase in 
glucose uptake. Upregulation of glucose transport across the plasma membrane is mediated by a 
family of facilitated glucose transporter proteins named (GLUT 1–14) (209,212); thus GLUT1, is 
expected to be upregulated in tumour cells. 
We analyzed the associations between MCTs, CD147, CD44 and GLUT1 Expression in CRC 
tissues, the results obtained are summarized in Table XX. 
 
Table XX: Assessment of associations between MCTs and CD147, CD44, and GLUT1 plasma membrane expression in 
tumour cases. 
 
 
CD147 
Plasma membrane 
CD44 
Plasma membrane 
GLUT1 
Plasma membrane 
Tumour n Positive (%) p n Positive (%) p n Positive (%) p 
MCT1          
Positive 452 157 (34.7%) 0.003 438 116 (26.5%) 0.111 425 126 (29.6%) 0.076 
MCT4          
Positive 269 100 (37.2%) 0.050 270 98 (36.3%) <0.001 262 90 (34.4%) 0.001 
 
 
We observed that in tumour samples, MCT1 positive cases were associated with CD147 
plasma membrane expression (p=0.003) and between MCT4 and both chaperones plasma 
membrane expression; CD147 (p=0.05), CD44 (p<0.001) and GLUT1 (p=0.001); while association 
between MCT1 isoform with the chaperone CD44 and the metabolic marker GLUT1 was not 
achieved (Table XX). 
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4.2.3 EVALUATION OF ASSOCIATIONS BETWEEN MCTS, CD147, CD44, GLUT1 
EXPRESSION IN CRC TISSUES AND EPIDEMIOLOGICAL DATA 
 
The results obtained are described in Table XXI, XXII and XXIII which summarizes the 
correlation between MCTs, chaperones, metabolic marker GLUT1 plasma membrane expression 
and the epidemiological data. 
 
Figure 21 – 25 describes MCT1, MCT4, CD147, CD44 and GLUT plasma membrane 
expression, respectively, by stage, colon and rectal cancer survival curve assessed by log-rank test. 
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Table XXI: Assessment of correlation between MCTs, CD147, CD44, and GLUT1 plasma membrane expression and clinical data.  
                  *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
MCT1 
 
 
 
MCT4 
 
 
 
CD147 
 
 
 
CD44 
 
 
 
GLUT1 
n 
Positive  
    (%) p  n 
Positive 
    (%) p  n 
Positive 
    (%) p  n 
Positive 
    (%) p  n 
Positive 
 (%) p 
 
Sex 
       Male 
       Female 
 
 
314 
186 
 
 
92.7 
92.5 
 
 
0.934 
 
 
 
 
 
302 
180 
 
 
57.3 
56.1 
 
 
0.801 
 
 
 
 
 
312 
182 
 
 
31.4 
35.2 
 
 
0.391 
 
 
 
 
 
302 
178 
 
 
25.5 
25.8 
 
 
0.933 
 
 
 
 
 
294 
169 
 
 
28.6 
28.4 
 
 
0.969 
 
Age        
      <=71.5 
      > 71.5 
 
 
253 
247 
 
 
91.3 
93.9 
 
 
0.263 
 
 
 
 
 
242 
240 
 
 
52.5 
61.3 
 
 
0.052 
 
 
 
 
 
250 
244 
 
 
28.8 
36.9 
 
 
0.056 
 
 
 
 
 
242 
238 
 
 
23.6 
27.7 
 
 
0.295 
 
 
 
 
 
231 
232 
 
 
28.6 
28.4 
 
 
0.977 
 
Personal history - Polyps 
       Negative          
       Positive 
 
 
435 
65 
 
 
92.4 
93.8 
 
 
0.681 
 
 
 
 
 
417 
65 
 
 
55.9 
63.1 
 
 
0.276 
 
 
 
 
 
431 
63 
 
 
32.5 
24.9 
 
 
0.700 
 
 
 
 
 
416 
64 
 
 
25.5 
26.6 
 
 
0.854 
 
 
 
 
 
402 
61 
 
 
28.6 
27.9 
 
 
0.905 
 
Personal history - CCR 
      Negative          
      Positive 
 
 
487 
13 
 
 
92.6 
92.3 
 
 
0.967 
 
 
 
 
 
469 
13 
 
 
56.1 
84.6 
 
 
0.040 
 
 
 
 
 
481 
13 
 
 
33.1 
23.1 
 
 
0.560* 
 
 
 
 
 
467 
13 
 
 
25.5 
30-8 
 
 
0.748* 
  
 
451 
12 
 
 
28.6 
25 
 
 
1.000* 
 
Personal history - cancer  
       Negative          
       Positive 
 
 
462 
38 
 
 
92.4 
94.7 
 
 
0.601 
 
 
 
 
 
444 
38 
 
 
56.8 
57.9 
 
 
0.892 
 
 
 
 
 
458 
36 
 
 
32.5 
36.1 
 
 
0.660 
 
 
 
 
 
443 
37 
 
 
25.3 
29.7 
 
 
0.552 
 
 
 
 
 
428 
35 
 
 
28.5 
28.6 
 
 
0.993 
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Table XXII: Assessment of correlation between MCTs, CD147, CD44, and GLUT1 plasma membrane expression and diagnosis/surgery data.       
     *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
 
MCT1 
 
 
 
MCT4 
 
 
 
CD147 
 
 
 
CD44 
 
 
 
GLUT1 
n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p 
 
Presentation 
     Asymptomatic 
     Symptomatic     
 
 
87 
413 
 
 
93.1 
92.5 
 
 
0.844 
 
 
 
 
 
84 
398 
 
 
48.8 
58.5 
 
 
0.102 
 
 
 
 
 
87 
407 
 
 
36.8 
31.9 
 
 
0.383 
 
 
 
 
 
85 
395 
 
 
18.8 
27.1 
 
 
0.113 
 
 
 
 
 
83 
380 
 
 
28.9 
28.4 
 
 
0.928 
 
Rectal Examination  
   Mobile cancer 
   Fixed cancer 
 
 
41 
27 
 
 
57.1 
42.9 
 
 
0.059 
 
 
 
 
 
 
40 
24 
 
 
43.3 
56.7 
 
 
0.003 
 
 
 
 
 
 
40 
26 
 
 
65.2 
34.8 
 
 
0.575 
 
 
 
 
 
 
39 
25 
 
 
46.2 
53.8 
 
 
0.221 
 
 
 
 
 
 
38 
22 
 
 
46.7 
53.3 
 
 
0.122 
 
Localization 
    Colon 
    Rectum 
 
 
360 
140 
 
 
92.5 
92.9 
 
 
0,891 
 
 
 
 
 
351 
131 
 
 
59.3 
50.4 
 
 
0.080 
 
 
 
 
 
359 
135 
 
 
33.4 
31.1 
 
 
0.625 
 
 
 
 
 
349 
131 
 
 
27.5 
20.6 
 
 
0.123 
 
 
 
 
 
338 
125 
 
 
29.3 
26.4 
 
 
0.541 
 
Macroscopic Cancer  type 
    Polypoid 
    Ulcerative 
     Infiltrative 
     Exophytic 
     Vilosous 
 
 
254 
116 
42 
42 
2 
 
 
92.9 
91.4 
85.7 
95.2 
100 
 
 
 
 
0.492 
 
 
 
 
 
 
 
247 
115 
40 
37 
2 
 
 
54.7 
54.8 
62.5 
70.3 
100 
 
 
 
 
0.245 
 
 
 
 
 
 
 
249 
118 
40 
41 
2 
 
 
33.3 
32.3 
27.5 
29.3 
0.0 
 
 
 
 
0.798 
 
 
 
 
 
 
 
246 
112 
39 
37 
2 
 
 
26.0 
25.0 
12.8 
32.4 
50.0 
 
 
 
 
0.294 
 
 
 
 
 
 
 
239 
111 
35 
34 
2 
 
 
23.8 
29.7 
25.7 
50.0 
0.0 
 
 
 
 
0.023 
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CEA ( ng/mL) 
   >5   
   ≥5 
 
122 
272 
 
90.2 
91.9 
 
0.568 
 
 
 
 
115 
269 
 
60.0 
57.6 
 
0.665 
 
 
 
 
118 
270 
 
33.1 
29.3 
 
0.455 
 
 
 
 
115 
263 
 
30.4 
22.8 
 
0.116 
 
 
 
 
111 
256 
 
36.9 
22.7 
 
0.05 
 
Metastasis 
    Hepatic  
                 Absent 
                 Present 
     Lymph Node  
                Absent 
                Present 
     Pulmonar                       
               Absent 
               Present 
 
 
 
428 
44 
 
439 
33 
461 
11 
 
 
 
93.5 
86.4 
 
93.4 
84.8 
93.3 
72.7 
 
 
 
0.083 
 
 
0.067 
 
 
0.009 
 
 
 
 
 
 
 
 
 
 
415 
40 
 
422 
33 
444 
11 
 
 
 
55.7 
62.5 
 
56.9 
48.5 
56.1 
63.6 
 
 
 
0.405 
 
 
0.350 
 
0.618 
 
 
 
 
 
 
 
 
 
 
427 
41 
 
436 
33 
 
458 
10 
 
 
 
31.9 
36.6 
 
32.2 
33.3 
 
32.3 
30.0 
 
 
 
0.536 
 
 
0.892 
 
 
1.000* 
 
 
 
 
 
 
 
 
 
413 
40 
 
420 
33 
 
442 
11 
 
 
 
23.7 
37.5 
 
24.8 
27.3 
 
24.9 
27.3 
 
 
 
0.055 
 
 
0.748 
 
 
1.000* 
 
 
 
 
 
 
 
 
 
 
399 
39 
 
409 
29 
 
427 
11 
 
 
 
26.1 
41.0 
 
28.1 
17.2 
 
27.4 
27.3 
 
 
 
0.046 
 
 
0.204 
 
 
1.000* 
 
Tumour Mobility  
    Mobile 
    Fixed 
 
 
433 
66 
 
 
92.1 
95.5 
 
 
0.340 
 
 
 
 
 
419 
62 
 
 
56.3 
59.7 
 
 
0.619 
 
 
 
 
 
428 
65 
 
 
31.3 
41.5 
 
 
0.101 
 
 
 
 
 
419 
60 
 
 
25.5 
26.7 
 
 
0851 
 
 
 
 
 
405 
57 
 
 
27.4 
36.8 
 
 
0.140 
 
Tumour Perforation 
    Absent 
    Present  
 
 
475 
25 
 
 
93.1 
84.0 
 
 
0.092 
 
 
 
 
 
460 
22 
 
 
56.5 
63.6 
 
 
0.510 
 
 
 
 
 
469 
25 
 
 
32.6 
36.0 
 
 
0.726 
 
 
 
 
 
457 
23 
 
 
25.8 
21.7 
 
 
0.662 
 
 
 
 
 
441 
22 
 
 
27.9 
40.9 
 
 
0.187 
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Table XXIII: Assessment of correlation between MCTs, CD147, CD44, and GLUT1 plasma membrane expression and pathological data.   
                     *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
 
MCT1 
 
 
 
MCT4 
 
 
 
CD147 
 
 
 
CD44 
 
 
 
GLUT1 
n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p 
 
Tumour size 
      ≤ 4.5 cm 
      > 4.5 cm 
 
 
286 
182 
 
 
93.4 
91.2 
 
 
0.389 
  
 
278 
175 
 
 
54.7 
60.0 
 
 
0.265 
  
 
283 
180 
 
 
27.9 
41.1 
 
 
0.003 
  
 
278 
173 
 
 
23.7 
28.3 
 
 
0.278 
  
 
267 
167 
 
 
29.6 
26.3 
 
 
0.466 
 
Macrosc. serosal involv. 
      Absent 
     Present 
 
 
124 
374 
 
 
91.9 
92.8 
 
 
0.756 
  
 
119 
361 
 
 
56.3 
56.8 
 
 
0.926 
  
 
120 
372 
 
 
30.0 
33.6 
 
 
0.465 
  
 
121 
357 
 
 
22.3 
26.9 
 
 
0.320 
  
 
115 
346 
 
 
22.6 
30.3 
 
 
0.111 
 
Synchronous tumours 
     Absent 
     Present 
 
 
482 
16 
 
 
92.5 
93.8 
 
 
0.855 
  
 
463 
17 
 
 
56.6 
58.8 
 
 
0.855 
  
 
476 
16 
 
 
32.8 
31.3 
 
 
0.898 
  
 
463 
15 
 
 
25.7 
26.7 
 
 
1.000* 
  
 
445 
16 
 
 
28.8 
18.8 
 
 
0.574* 
 
Histological Type 
    Adenocarcinoma 
    Mucinous 
    Invasive Adenocarc. 
    Signet ring and mucinous
 
 
417 
51 
24 
4 
 
 
92.8 
90.2 
95.8 
75.0 
 
 
 
0.456 
  
 
402 
49 
24 
3 
 
 
57.0 
57.1 
54.2 
33.3 
 
 
 
0.862 
  
 
411 
52 
23 
4 
 
 
33.6 
28.8 
26.1 
25.0 
 
 
 
0.787 
  
 
399 
49 
24 
4 
 
 
26.6 
16.5 
16.7 
0.0 
 
 
 
0.463 
  
 
386 
46 
23 
4 
 
 
28.2 
26.1 
39.1 
0.0 
 
 
 
0.389 
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Differentiation 
   Well-differentiated 
    Moderately-diff. 
    Poorly-diff. 
    Undifferentiated 
 
219 
209 
49 
4 
 
93.2 
93.3 
85.7 
100.0 
 
 
0.271 
  
213 
204 
43 
3 
 
56.8 
55.4 
69.8 
0.0 
 
 
0.070 
  
217 
206 
48 
4 
 
34.6 
32.5 
29.2 
25.0 
 
 
0.875 
  
211 
202 
45 
4 
 
24.6 
27.2 
33.3 
0.0 
 
 
0.399 
  
202 
197 
43 
3 
 
21.3 
35.0 
39.5 
33.3 
 
 
0.009 
 
Tumour Penetration 
     Tis 
     T1/T2 
     T3/T4  
 
 
5 
89 
395 
 
 
100.0 
92.1 
92.4 
 
 
 
0.810 
  
 
6 
86 
380 
 
 
16.7 
54.7 
57.6 
 
 
 
0.123 
  
 
4 
22 
391 
 
 
25.0 
24.7 
34.8 
 
 
 
0.179 
  
 
5 
87 
379 
 
 
0.0 
24.1 
26.9 
 
 
 
0.355 
  
 
5 
82 
367 
 
 
0 
24.4 
30.0 
 
 
 
0.218 
 
Spread to lymph nodes 
       Absent 
       Present 
 
 
280 
204 
 
 
92.5 
92.2 
 
 
0.888 
  
 
272 
196 
 
 
54.0 
59.2 
 
 
0.269 
  
 
277 
202 
 
 
32.5 
33.2 
 
 
0.876 
  
 
274 
192 
 
 
25.9 
26.0 
 
 
0.975 
  
 
263 
187 
 
 
25.5 
33.7 
 
 
0.058 
 
 Vessel  invasion 
      Absent 
      Present 
 
 
159 
314 
 
 
94.3 
91.4 
 
 
0.255 
  
 
159 
299 
 
 
58.5 
55.5 
 
 
0.541 
  
 
156 
313 
 
 
33.3 
32.3 
 
 
0.817 
  
 
158 
299 
 
 
31.6 
22.4 
 
 
0.031 
  
 
150 
291 
 
 
25.3 
31.3 
 
 
0.194 
 
Surgical margin invasion 
      Absent 
      Present 
 
 
473 
13 
 
 
92.6 
84.6 
 
 
0.284 
  
 
456 
13 
 
 
55.7 
76.9 
 
 
0.128 
  
 
468 
13 
 
 
32.7 
46.2 
 
 
0.309 
  
 
455 
13 
 
 
25.5 
46.2 
 
 
0.094 
  
 
441 
10 
 
 
28.8 
40.0 
 
 
0.486* 
TNM 
     Stage 0 
     Stage I 
     Stage II 
     Stage III 
     Stage IV 
 
1 
76 
183 
155 
75 
 
100.0 
92.1 
92.9 
94.2 
88.0 
 
 
 
0.566 
  
2 
75 
179 
151 
67 
 
0.0 
52.0 
57.0 
57.6 
59.7 
 
 
 
0.464 
  
0 
77 
181 
154 
73 
 
0.0 
22.1 
36.5 
34.4 
31.5 
 
 
 
0.147 
  
1 
76 
178 
147 
70 
 
0.0 
21.1 
28.1 
24.5 
30.0 
 
 
 
0.649 
  
1 
73 
173 
142 
66 
 
0.0 
23.3 
26.0 
30.3 
39.4 
 
 
 
0.206 
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                    Stage I (p=0.586)                 Stage II (p=0.294)                        Stage III (p=0.986)                                     Stage IV (p=0.017) 
                      
                     Stage I (p=0.562)                Stage II (p=0.411)                                     Stage III (p=0.851)                                       Stage IV (p=0.845) 
 
Figure 21: Kaplan-Meyer survival curves of MCT1 plasma membrane expression in colon and rectum, by stage. 
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                       StageI (p=0.775)                                      Stage II   (p=0.350)                Stage III (p=0.060)                               Stage IV (p=0.314)       
 
    
                        Stage I   (p=0.680)                    Stage II   (p=0.545)                Stage III (p=0.438)                                   Stage IV (p=0.779)       
 
Figure 22: Kaplan-Meyer survival curves of MCT4 plasma membrane expression in colon and rectum, by stage. 
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                     Stage I   (p=0.424)   Stage II   (p=0.340)                                  Stage III (p=0.850)                                  Stage IV (p=0.761) 
 
     
                      Stage I   (p=0.208)                              Stage II   (p=0.253)                                   Stage III (p=0.414)                                   Stage IV (p=0.298) 
 
Figure 23: Kaplan-Meyer survival curves of CD147 plasma membrane expression in colon and rectum, by stage. 
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                     Stage I   (p=0.209)                               Stage II   (p=0.580)                                   Stage III   (p=0.580)                                Stage IV  (p=0.233) 
 
      
                      Stage I   (p=0.503)                               Stage II   (p=0.115)            Stage III   (p=0.965)                                  Stage IV (p=0.787) 
 
Figure 24: Kaplan-Meyer survival curves of CD44 plasma membrane expression in colon and rectum, by stage. 
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                     Stage I   (p=0.989)                  Stage II   (p=0.441)            Stage III   (p=0.901)                                 Stage IV  (p=0.952) 
   
  
                     Stage I   (p=0.023)    Stage II   (p=0.305)               Stage III   (p=0.754)                                 Stage IV (p=0.216)  
 
Figure 25: Kaplan-Meyer survival curves of GLUT1 plasma membrane expression in colon and rectum, by stage. 
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Assessment of correlation between MCTs, chaperones, metabolic marker GLUT1 plasma 
membrane expression and clinical data revealed MCT4 positive cases were associated with 
“Personal History of CRC” (p=0.040) and a tendency for  association between MCT4 and CD147 
with “Age” (p=0.052 and p=0.056, respectively) (Table XXI). 
When analyzing correlation between plasma membrane expression and data from 
diagnosis/surgery data we found association between MCT1 plasma membrane expression and with 
“Pulmonary Metastasis” (p=0.009) and a tendency to association with “Rectal Examination” 
(p=0.059) “Hepatic and Ganglionar Metastasis” (respectively p=0.083 and p=0.067). MCT4 plasma 
membrane expression showed association with “Rectal Examination” (p=0.003). CD44 showed a 
tendency to associate with “Hepatic Metastasis” (p=0.055) and GLUT1 plasma membrane 
expression showed association with “Macroscopic cancer type” (p=0.023); “CEA” (p=0.05) and 
“Hepatic Metastasis” (p=0.046) (Table XXII).  
When analyzing the correlation between plasma membrane expression and pathological 
data we find association between CD147 plasma membrane and “Tumour size” (p=0.003); CD44 
plasma membrane expression and “Vessel Invasion” (p=0.031) and GLUT1 plasma membrane 
expression and “Tumour Differentiation” (p=0.009) (Table XXIII). 
Observing colon and rectal cancer survival curves assessed by log-rank test, of MCTs, 
chaperones and GLUT1, (Figures 21-25), we found a statistically significant association for MCT1 
expression and stage IV for colon cancer (p=0.017); GLUT1 expression and stage I for rectal cancer 
(p=0.023) and a tendency to association between MCT4 expression and stage III for colon cancer 
(p=0.060). 
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4.3 ANALYSIS OF THE ASSOCIATIONS OF MCTS, CHAPERONES AND GLYCOLYTIC 
METABOLIC MARKERS IN COLORECTAL CANCER HEPATIC METASTASIS AND NORMAL ADJACENT 
TISSUES  
 
Liver is the most common site of CRC metastasis (50-60% of the cases). Close to one third 
of patients have liver metastases either at the time of diagnosis (synchronous in 1/3 of the cases) or 
during the disease course (metachronous in 2/3 of the cases) (312–314)  and about 66% had liver 
metastases at death time (315,316). Despite recent advances in terms of early diagnosis and 
therapy which led to improvement in survival (five years survival has increased from <8%, using 
palliative chemotherapy to 25-40% using multimodal management including palliative chemotherapy 
and surgery (312,313,317), the prognosis remains reserved (312–316), with a five years survival of 
15-50%  and 17-33% ten years survival after hepatic metastases resection (315,316). 
Surgical resection of liver metastases is considered the only curative treatment option for 
patients with resectable liver metastases and no extrahepatic disease (312–314) but liver 
metastases are resectable in only 15% of the cases. The remaining 85% are ineligible to surgery 
because of the location, size, number, residual normal liver, and the extra hepatic disease 
(312,313,318). Recently, other new modalities have become available that allow safe ablation of 
liver metastases without the need for surgical intervention. 
Once documented the increases expression of MCTs, CD147 and CD44 chaperones and 
glycolytic metabolic marker GLUT1 in CRC tissues remains the question if that metabolic profile is 
maintained in CRC hepatic metastasis. Our initial aim was to evaluate the expression of these 
proteins in the patients with liver metastasis of our series, but due to the few number of patients that 
have been submitted to hepatic resection during this period, this was not possible. Thus, we 
increased the research period of patients submitted to CRC hepatic metastasis resection from 
January 2003 to January 2011 and analyzed the expression of MCT4, CD147, CD44 and GLUT1 in 
CRC hepatic metastasis and normal adjacent tissue.  
No data exists in the literature about the expression of these proteins in CRC hepatic 
metastasis, being this the first study to be performed in this direction.    
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4.3.1 Characterization of MCT4, CD147, CD44 and GLUT1 
Immunohistochemical Expression in CRC Hepatic Metastasis and Normal Adjacent 
Tissue 
A total of 45 samples of hepatic metastasis of CRC patients were analyzed, including tumour 
and normal adjacent tissue. Sections were evaluated for immunoreaction, which included both 
cytoplasmic and membrane-positive staining. The results obtained are described in Table XXIV, 
which summarizes the frequency of MCT 4, chaperones CD147 and CD44 and glycolytic metabolic 
marker GLUT1 expressions, in tumour cells and normal adjacent epithelium. 
MCT1 immunohistochemical reaction was not performed due to problems with the 
“detection system”. 
 
Figure 26 shows representative pictures of MCT4, CD147, CD44 and GLUT1 positive 
staining in CRC Hepatic Metastasis and in normal adjacent epithelium. 
 
Table XXIV: Pattern of protein staining in CRC Hepatic metastasis vs. normal adjacent epithelium. 
 
Protein 
 
Immunoreaction Plasma membrane 
 n Positive (%) p Positive (%) p 
MCT4   0.749  <0.001 
            NA 
           Tumour 
40 
44 
15 (37.5%) 
18 (40.9%) 
 0 (0%) 
275 (40.9%) 
 
CD147   0.616  0.001 
            NA 
           Tumour 
40 
43 
29 (72.5%) 
29 (67.4%) 
 12 (30.0 %) 
29 (67.4%) 
 
CD44   <0.001  <0.001 
            NA 
           Tumour 
41 
41 
0 (0.0%) 
12 (27.3%) 
 0 (0.0%) 
12 (27.3%) 
 
GLUT1   <0.001  <0.001 
            NA 
           Tumour 
43 
44 
0 (0.0%) 
25 (56.8%) 
 0 (0.0%) 
25 (56.8%) 
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Figure 26: MCT4, CD147, CD44 and GLUT1 immunohistochemical expression in CRC Hepatic Metastasis samples       
                  (200x magnification). 
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Observing the results of Table XXIV, in tumour positive cases, immunoreaction and plasma 
membrane shows similar results. All the proteins studied are overexpressed in CRC hepatic 
metastasis when comparing with normal-adjacent tissue in plasma membrane expression pattern 
(p<0.001). The values were lower in normal adjacent tissue and no reaction was observed for 
MCT4, CD44 and GLUT1.     
 
4.3.2 EVALUATION OF ASSOCIATIONS BETWEEN MCT4, CD147, CD44 AND GLUT1 
EXPRESSION IN CRC HEPATIC METASTASIS 
 
We analyzed the associations between MCT4, CD147, CD44 and GLUT1 expression in CRC 
hepatic metastasis, the results obtained are summarized in Table XXV. 
 
Table XXV: Assessment of associations between MCTs and CD147, CD44, and GLUT1 plasma membrane expression in 
CRC Hepatic metastases. 
 
 
 
CD147 
Plasma membrane 
CD44 
Plasma membrane 
GLUT1 
Plasma membrane 
Tumour n Positive (%) p n Positive (%) p n Positive (%) p 
MCT4   <0.001   0.003*   <0.001 
Positive 18 16  
(88.9%) 
 18 7 
(38.9%) 
 18 18 (100%)  
 
* Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
We observed that in tumour samples, MCT4 positive cases were associated with CD147 
plasma membrane expression (p <0.001) CD44 plasma membrane expression (p =0.003) and 
GLUT1 plasma membrane expression (p <0.001) (Table XXVI). 
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4.3.3 EVALUATION OF ASSOCIATIONS BETWEEN MCT4, CD147, CD44, GLUT1 
EXPRESSION IN CRC HEPATIC METASTASIS AND EPIDEMIOLOGICAL DATA 
 
Data from these 45 patients with CRC Hepatic metastasis were retrospectively collected 
namely anatomopathological data from primary tumour (CRC localization, stage, differentiation, 
lymphatic and blood vessel invasion) and anatomopathological data from hepatic metastasis 
(presence of synchronous or metachronous hepatic metastasis, localization, size). Other data that 
were also collected was CEA level at CRC diagnosis and Hepatic metastasis diagnosis. 
The results obtained are described in Table XXVI and XXVII which summarizes the 
correlation between MCT4, chaperones and metabolic marker GLUT1 plasma membrane expression 
and anatomopathological data from primary tumour and hepatic metastasis. 
 
 Figures 27 – 30 outline MCT4, CD147, CD44 and GLUT1 plasma membrane expression 
CRC Hepatic metastasis survival curves assessed by log-rank test, respectively. 
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Table XXVI: Assessment of correlation between MCT4, CD147, CD44, and GLUT1 plasma membrane expression and anatomopathological data from primary tumour.                
*Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MCT4 
 
 
 
CD147 
 
 
 
CD44 
 
 
 
GLUT1 
n 
Positive 
     (%) p  
Positive 
     (%) p  
Positive 
     (%) p  
Positive 
     (%) p 
Localization 
    Colon 
    Rectum 
 
7 
37 
 
28.6 
43.2 
 
0.682 
  
42.9 
72.2 
 
0.190 
  
42.9 
24.3 
 
0.369 
  
42.9 
59.5 
 
0.443 
CRC stage 
    I+II 
    III+IV 
 
8 
32 
 
62.5 
37.5 
 
0.250 
  
75.0 
67.7 
 
1.000 
  
25.0 
28.1 
 
1.000 
  
62.5 
56.3 
 
1.000 
Differentiation 
    Well/ Moderately-diff. 
    Poorly/ Undifferentia. 
 
20 
17 
 
35.0 
47.1 
 
0.457 
  
60.0 
81.3 
 
0.277 
  
30.0 
29.4 
 
0.969 
  
45.0 
70.6 
 
0.117 
Venous Vessel  invasion 
      Absent 
      Present 
 
20 
11 
 
45.0 
27.3 
 
0.452 
  
84.2 
45.5 
 
0.042 
  
20.0 
45.5 
 
0.217 
  
55.0 
50.0 
 
0.784 
Lymph Vessel  invasion 
      Absent 
      Present 
 
23 
9 
 
30.4 
66.7 
 
0.109 
  
72.7 
66.7 
 
1.000 
  
17.4 
55.6 
 
0.075 
  
43.5 
80.0 
 
0.070 
 
 
CEA 
      ≤ 200ng/ml 
      > 200ng/ml 
 
24 
3 
 
41.7 
0.0 
 
0.274* 
  
62.5 
66.7 
 
 
1.000* 
  
25.0 
33.3 
 
1.000* 
  
58.3 
33.3 
 
0.569* 
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Table XXVII: Assessment of correlation between MCT4, CD147, CD44, and GLUT1 plasma membrane expression and anatomopathological data from hepatic metastasis.                            
                     *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MCT4 
 
 
 
CD147 
 
 
 
CD44 
 
 
 
GLUT1 
n Positive 
     (%) 
p 
 
Positive 
     (%) 
p 
 
Positive 
     (%) 
p 
 
Positive 
     (%) 
p 
 
Localization 
    One hepatic lobe 
    Both  hepatic lobe 
 
 
30 
9 
 
 
50.0 
22.2 
 
 
0.251 
  
 
73.3 
44.4 
 
 
0.129 
  
 
26.7 
33.3 
 
 
0.693 
  
 
60.0 
62.5 
 
 
1.000 
 
Size 
    ≤ 5 cm 
    > 5 cm 
 
 
37 
6 
 
 
43.2 
33.3 
 
 
1.000 
  
 
70.3 
50.0 
 
 
0.373 
  
 
27.0 
33.3 
 
 
1.000 
  
 
58.3 
50.0 
 
 
1.000 
 
CEA 
      ≤ 200ng/ml 
      > 200ng/ml 
 
 
35 
4 
 
 
45.7 
25.0 
 
 
0.618* 
  
 
64.7 
75.0 
 
 
1.000* 
  
 
25.7 
25.0 
 
 
1.000* 
  
 
57.1 
50.0 
 
 
1.000* 
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           p=0.578           p=0.491 
       
 
 
 
 
 
 
  p=0.274           p=0.727 
 
 
                                                                                                
Figure 27: MCT4 plasma membrane expression CRC 
Hepatic metastasis survival curve assessed by log-rank test. 
Figure 28: CD147 plasma membrane expression CRC 
Hepatic metastasis survival curve assessed by log-rank test. 
Figure 30: CD44 plasma membrane expression CRC 
Hepatic metastasis survival curve assessed by log-rank test. 
Figure 29: GLUT1 plasma membrane expression CRC 
Hepatic metastasis survival curve assessed by log-rank 
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Assessment of correlation between MCT4, chaperones and the metabolic marker GLUT1 
plasma membrane expression and anatomopathological data from primary tumour and Hepatic 
metastasis, revealed CD147 positive cases were associated with “Venous vessel invasion” of CRC  
(p=0.042, Table XXVI) and no correlation was observed with anatomopathological data from 
Hepatic metastasis (Table XXVII). 
 
 
 No statistic significant associations were found for MCT4, CD147, CD44 and GLUT1 plasma 
membrane expression in CRC Hepatic metastasis survival curve assessed by log-rank test (Figures 
27 – 30). 
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4.4 ANALYSIS OF THE ASSOCIATIONS OF VEGF’S FAMILY IN PRIMARY COLORECTAL 
TUMOURS AND NORMAL ADJACENT TISSUES  
 
Angiogenesis plays a key role in tumourigenesis and metastatic processes (4,229–234) and 
VEGF represents a critical inducer of tumour angiogenesis (234,258,259). In mammals, VEGF 
family consists of VEGF-A, B, C, D and PlGF1 and 2. All VEGF molecules/ligands transduce their 
signal through their binding to VEGF receptor -1, -2 and -3. VEGFR-2 is the key molecule for VEGF 
signaling in the tumour micro-environment including vascular permeability and endothelial cell 
proliferation (259,260), VEGFR-3 is restricted to lymphatic vessels after their formation (271,274).  
 We evaluated VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 immunohistochemical expression in 
CRCs and Normal Adjacent Tissue, in this series of 580 cases and also the correlation with clinical 
data.  
 
4.4.1 CHARACTERIZATION OF VEGF-A, VEGF-C, VEGFR-2 AND VEGFR-3 
IMMUNOHISTOCHEMICAL EXPRESSION IN CRCS AND NORMAL ADJACENT TISSUES 
 
The results obtained are described in Table XXVIII which summarizes the frequency of 
VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expressions, in tumour cells and normal adjacent 
epithelium. 
Analyzing the results of Table XXVIII, it is possible to observe that only VEGF-C are 
overexpressed in tumours when comparing tumour cell with normal-adjacent tissue (p=0.004), and 
VEGFR-2 shows a tendency to that association (p=0.064).  
 
Figure 31 shows representative cases of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 positive 
staining in tumour cells and in normal adjacent epithelium. 
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Table XXVIII: Pattern of protein staining in CRC vs. normal adjacent epithelium. 
 
Protein  Immunoreaction 
 n Positive (%) p 
VEGF-A   1.000* 
           NA 
           Tumour 
132 
500 
130 (98.5%) 
490 (98.0%) 
 
VEGF-C   0.004 
            NA 
           Tumour 
138 
508 
115 (83.3%) 
466 (91.7%) 
 
VEGFR-2   0.064 
            NA 
           Tumour 
142 
501 
133 (93.7%) 
486 (97.0%) 
 
VEGFR-3   0.903 
            NA 
           Tumour 
139 
505 
34 (24.5%) 
121 (24.0%) 
 
 
Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
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Figure 31:  VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 immunohistochemical expression in CRC samples  
                    (40x magnification). 
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4.4.2 EVALUATION OF ASSOCIATIONS BETWEEN VEGF-A, VEGF-C, AND VEGFR-2, 
VEGFR-3 EXPRESSION IN CRC TISSUES 
 
VEGF molecules transduce their signal through their binding to VEGF receptor -1, -2 and -3 
(259,260). VEGFR-2 is considered the primary signaling receptor for VEGF during angiogenesis 
(259,319) and although VEGFR-3 is restricted to lymphatic and some fenestrated vascular 
endothelium in the adult, it is upregulated in angiogenic blood vessels in tumours, and blocking 
VEGFR-3 inhibits angiogenesis and growth in some tumours (320). 
 
We analyzed the associations between VEGF-A, VEGF-C and the receptors VEGFR-2, VEGFR-
3 expression in CRC tissues, the results obtained are summarized in Table XXIX. 
 
 
Table XXIX: Assessment of associations between VEGF-A, VEGF-C and the receptors VEGFR-2 and VEGFR-3 expression  
                    in tumour cases. 
 
 
 VEGFR-2 
Immunoreaction 
VEGFR-3 
Immunoreaction 
Tumour n 
Positive 
     (%) 
p n 
Positive 
     (%) 
p 
VEGF-A   1.000*   0.210* 
Positive 464 453 (97.6%)  471 120 (25.5%)  
VEGF-C   1.000*   0.047* 
Positive 446 434 (97.3%)  451 117 (25.9%)  
       
 
* Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
We observed that in tumour samples, VEGF-C positive cases were associated with VEGFR-3 
expression (p=0.047) (Table XXIX). 
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4.4.3 EVALUATION OF ASSOCIATIONS BETWEEN VEGF-A, VEGF-C, AND VEGFR-2, 
VEGFR-3 EXPRESSION IN CRC TISSUES AND EPIDEMIOLOGICAL DATA 
 
The results obtained are described in Table XXX, XXXI and XXXII which summarizes the 
correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression and epidemiological data. 
 
Figure 34, 35, 36 and 37 describes VEGF-A, VEGF-C, and VEGFR-2, VEGFR-3 plasma 
expression, respectively, by stage, colon and rectal cancer survival curve assessed by log-rank test. 
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Table XXX: Assessment of correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression and clinical data.          
     *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VEGFA 
 
 
 
VEGFC 
 
 
 
VEGFR-2 
 
 
 
VEGFR-3 
n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p  n 
Positive  
    (%) p 
 
Gender 
       Male 
       Female 
 
 
304 
181 
 
 
99.3 
96.1 
 
 
0.016* 
  
 
309 
184 
 
 
91.6 
93.5 
 
 
0.446 
  
 
306 
179 
 
 
97.1 
97.8 
 
 
0.776* 
  
 
307 
182 
 
 
24.4 
25.8 
 
 
0.731 
 
Age        
      <=71.5 
      > 71.5 
 
 
242 
242 
 
 
97.9 
98.3 
 
 
1.000* 
  
 
249 
229 
 
 
90.4 
94.2 
 
 
0.107 
  
 
244 
240 
 
 
97.1 
97.5 
 
 
0.802 
  
 
247 
241 
 
 
23.9 
26.1 
 
 
0.565 
 
Personal history-Polyps 
       Negative          
       Positive 
 
 
419 
66 
 
 
98.3 
97.0 
 
 
0.352* 
  
 
427 
66 
 
 
92.0 
93.9 
 
 
0.804* 
  
 
420 
65 
 
 
97.4 
96.9 
 
 
0.689* 
  
 
423 
66 
 
 
25.8 
19.7 
 
 
0.289 
 
Personal history - CCR 
      Negative          
      Positive 
 
 
472 
13 
 
 
98.3 
92.3 
 
 
0.219* 
  
 
480 
13 
 
 
92.3 
92.3 
 
 
1.000* 
  
 
472 
13 
 
 
97.2 
100.0 
 
 
1.000* 
  
 
476 
13 
 
 
25.2 
15.4 
 
 
0.533* 
 
Personal history of Cancer 
       Negative          
       Positive 
 
 
446 
39 
 
 
98.2 
97.4 
 
 
0.533* 
  
 
454 
39 
 
 
91.6 
100.0 
 
 
0.060 
  
 
447 
38 
 
 
97.1 
100.0 
 
 
0.612* 
  
 
450 
39 
 
 
25.6 
17.9 
 
 
0.292 
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Table XXXI: Assessment of correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression and diagnosis/surgery data.                                                  
                    *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
 
VEGFA 
 
 
 
VEGFC 
 
 
 
VEGFR-2 
 
 
 
VEGFR-3 
n Positive  
    (%) 
p 
 
n Positive  
    (%) 
p 
 
n Positive  
    (%) 
p 
 
n Positive  
    (%) 
p 
 
Presentation 
     Asymptomatic 
     Symptomatic     
 
 
87 
398 
 
 
96.6 
98.5 
 
 
0.207* 
  
 
89 
404 
 
 
88.8 
93.1 
 
 
0.168 
  
 
87 
398 
 
 
97.7 
97.2 
 
 
1.000* 
  
 
88 
401 
 
 
23.9 
25.2 
 
 
0.795 
 
Rectal Examination  
   Mobile cancer 
   Fixed cancer 
 
 
40 
25 
 
 
97.5 
100.0 
 
 
1.000* 
  
 
42 
25 
 
 
81.0 
92.0 
 
 
0.300* 
  
 
40 
25 
 
 
90.0 
92.0 
 
 
1.000* 
  
 
40 
24 
 
 
25.0 
12.5 
 
 
0.339* 
 
Localization 
    Colon 
    Rectum 
 
 
352 
133 
 
 
98.3 
97.7 
 
 
0.711* 
  
 
357 
136 
 
 
93.8 
88.2 
 
 
0.037 
  
 
354 
131 
 
 
98.0 
95.4 
 
 
0.115 
  
 
358 
131 
 
 
24.6 
26.0 
 
 
0.756 
 
Macroscopic Cancer  type 
    Polypoid 
    Ulcerative 
     Infiltrative 
     Exophytic 
     Vilosous 
 
 
244 
112 
38 
38 
2 
 
 
98.0 
97.4 
97.4 
100.0 
100.0 
 
 
 
 
0.896 
  
 
255 
115 
39 
37 
1 
 
 
89.8 
94.8 
94.9 
97.4 
50.0 
 
 
 
 
0.048 
  
 
246 
115 
40 
35 
2 
 
 
98.0 
98.3 
97.5 
92.1 
100.0 
 
 
 
 
0.278 
  
 
252 
114 
38 
39 
2 
 
 
25.4 
25.4 
13.2 
28.2 
50.0 
 
 
 
 
0.439 
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CEA ( ng/mL) 
   <5 
   ≥5 
 
 
 
 
314 
78 
 
 
 
 
94.9 
93.6 
 
 
 
 
1.000* 
  
 
 
 
314 
78 
 
 
 
 
90.1 
89.7 
 
 
 
 
0.869 
  
 
 
 
314 
78 
 
 
 
 
93.9 
94.9 
 
 
 
 
0.756 
  
 
 
 
313 
78 
 
 
 
 
24.6 
23.1 
 
 
 
 
0.779 
 
Metastasis 
    Hepatic  
                 Absent 
                 Present 
     
    Lymph Node  
                Absent 
                Present 
 
 
 
 
443 
39 
 
 
 
 
 
437 
45 
 
 
 
 
98.2 
97.4 
 
 
 
 
 
98.2 
97.8 
 
 
 
 
0.535* 
 
 
 
 
 
 
0.589* 
  
 
 
 
450 
40 
 
 
 
 
 
442 
48 
 
 
 
 
92.2 
92.5 
 
 
 
 
 
92.3 
91.7 
 
 
 
 
1.000* 
 
 
 
 
 
 
0.779* 
  
 
 
 
443 
39 
 
 
 
 
 
436 
46 
 
 
 
 
97.1 
100 
 
 
 
 
 
97.5 
95.7 
 
 
 
 
0.613* 
 
 
 
 
 
 
0.357* 
  
 
 
 
445 
41 
 
 
 
 
 
438 
48 
 
 
 
 
23.8 
39.0 
 
 
 
 
 
25.8 
18.8 
 
 
 
 
0.032 
 
 
 
 
 
 
0.285 
 
Tumour Mobility  
    Mobile 
    Fixed 
 
 
418 
63 
 
 
97.8 
100.0 
 
 
0.240 
  
 
426 
63 
 
 
91.8 
96.8 
 
 
0.158 
  
 
419 
62 
 
 
97.4 
96.8 
 
 
0.786 
  
 
423 
62 
 
 
24.6 
27.4 
 
 
0.630 
 
Tumour Perforation 
    Absent 
    Present  
 
 
460 
25 
 
 
98.0 
100.0 
 
 
0.480 
  
 
468 
25 
 
 
92.3 
92.0 
 
 
1.000* 
  
 
461 
24 
 
 
97.6 
91.7 
 
 
0.079 
  
 
464 
25 
 
 
24.6 
32.0 
 
 
0.403 
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Table XXXII: Assessment of correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression and pathological data.                   
                     *Comparisons were examined for statistical significance using Fisher’s exact test (when n < 5). 
 
 
 
 
VEGFA 
 
 
 
VEGFC 
 
 
 
VEGFR-2 
 
 
 
VEGFR-3 
n Positive  
    (%) 
p 
 
n Positive  
    (%) 
p 
 
n Positive  
    (%) 
p 
 
n Positive  
    (%) 
p 
 
Tumour size 
      ≤ 4.5 cm 
      > 4.5 cm 
 
 
281 
175 
 
 
97.5 
99.4 
 
 
0.161* 
  
 
281 
181 
 
 
94.3 
90.1 
 
 
0.088 
  
 
276 
178 
 
 
98.2 
96.6 
 
 
0.291 
  
 
277 
181 
 
 
27.1 
22.7 
 
 
0.287 
 
Macrosc. serosal involv. 
      Absent 
     Present 
 
 
121 
362 
 
 
97.5 
98.3 
 
 
0.697* 
  
 
122 
369 
 
 
89.3 
93.2 
 
 
0.164 
  
 
119 
364 
 
 
99.2 
96.7 
 
 
0.202* 
  
 
119 
368 
 
 
25.2 
24.5 
 
 
0.868 
 
Synchronous tumours 
     Absent 
     Present 
 
 
467 
16 
 
 
98.1 
100.0 
 
 
1.000* 
  
 
475 
16 
 
 
92.2 
93.8 
 
 
1.000* 
  
 
467 
16 
 
 
97.2 
100.0 
 
 
1.000* 
  
 
471 
16 
 
 
24.6 
25.0 
 
 
1.000* 
 
Histological Type 
    Adenocarcinoma 
    Mucinous 
    Invasive Adenocarc. 
    Signet ring and mucinous 
 
 
403 
50 
25 
3 
 
 
98.3 
98.0 
96.0 
100.0 
 
 
 
0.869 
  
 
408 
52 
25 
4 
 
 
92.6 
90.4 
96.0 
75.0 
 
 
 
0.470 
  
 
404 
49 
24 
4 
 
 
98.0 
93.9 
100.0 
75.0 
 
 
 
0.007 
  
 
403 
53 
25 
4 
 
 
26.1 
15.1 
28.0 
0.0 
 
 
 
0.214 
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Differentiation 
   Well-differentiated 
    Moderately-diff. 
    Poorly-diff. 
    Undifferentiated 
209 
208 
48 
2 
99.0 
97.6 
97.9 
66.7 
 
0.001 
215 
208 
48 
4 
92.6 
94.2 
89.6 
50.0 
 
0.007 
210 
205 
47 
4 
97.1 
97.6 
97.9 
100.0 
 
0.973 
212 
206 
49 
4 
23.6 
27.7 
22.4 
0.0 
 
0.474 
 
Tumour Penetration 
     Tis 
     T1/T2 
     T3/T4 
 
 
5 
87 
387 
 
 
100.0 
96.6 
98.4 
 
 
 
0.476 
 
  
 
5 
88 
394 
 
 
80.0 
85.2 
94.2 
 
 
 
0.010 
  
 
4 
87 
388 
 
 
100.0 
97.7 
97.4 
 
 
 
0.939 
  
 
5 
85 
393 
 
 
20.0 
27.1 
24.2 
 
 
 
0.830 
 
Spread to nearby lymphnodes 
       Absent 
       Present 
 
 
277 
194 
 
 
97.8 
98.5 
 
 
0.742* 
  
 
276 
203 
 
 
92.4 
93.1 
 
 
0.767 
  
 
273 
198 
 
 
97.4 
97.0 
 
 
0.782* 
  
 
273 
202 
 
 
24.2 
25.7 
 
 
0.696 
 
Vessel  invasion 
      Absent 
      Present 
 
 
166 
301 
 
 
98.2 
98.0 
 
 
0.889 
  
 
166 
308 
 
 
92.2 
92.2 
 
 
0.988 
  
 
163 
303 
 
 
97.5 
97.0 
 
 
0.747 
  
 
164 
306 
 
 
23.2 
25.5 
 
 
0.578 
 
Surgical margin invasion 
      Absent 
      Present 
 
 
460 
13 
 
 
98.0 
100.0 
 
 
1.000* 
  
 
468 
13 
 
 
92.5 
84.6 
 
 
0.264* 
  
 
459 
13 
 
 
97.2 
100.0 
 
 
1.000* 
  
 
465 
12 
 
 
24.3 
33.3 
 
 
0.500* 
TNM 
     Stage 0 
     Stage I 
     Stage II 
     Stage III 
     Stage IV 
 
1 
76 
183 
147 
70 
 
100.0 
96.1 
98.4 
98.6 
98.6 
 
 
 
0.713 
  
1 
76 
181 
156 
71 
 
100.0 
86.8 
94.5 
92.3 
93.0 
 
 
 
0.336 
  
1 
75 
180 
150 
70 
 
100.0 
98.7 
97.2 
96.7 
97.1 
 
 
 
0.940 
  
1 
74 
180 
154 
72 
 
0.0 
28.4 
21.7 
24.7 
30.6 
 
 
 
0.550 
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                     Stage I   (p=0.828)                    Stage II   (p=0.397)              Stage III   (p=0.351)                                             Stage IV*    
                        
 
 
 
 
 
 
 
 
                      Stage I   (p=0.724)                              Stage II*                                                     Stage III*                           Stage IV (p=0.120) 
 
Figure 32: Kaplan-Meyer survival curves of VEGF-A plasma membrane expression in colon and rectum, by stage.               
*no comparasion was realized, because all cases are VEGF-A+ 
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                      Stage I   (p=0.574)                   Stage II   (p=0.144)              Stage III   (p=0.176)                                  Stage IV (p=0.700)   
   
   
 
 
 
 
 
 
 
                     Stage I   (p=0.421)                   Stage II   (p=0.567)                Stage III   (p=0.019)                                 Stage IV (p=0.946) 
 
Figure 33: Kaplan-Meyer survival curves of VEGF-C plasma membrane expression in colon and rectum, by stage.  
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                                  Stage I*                        Stage II   (p=0.498)              Stage III   (p=0.532)                                  Stage IV (p=0.683) 
            
 
 
 
 
 
 
 
                    
 
                      Stage I   (p=0.764)                      Stage II   (p=0.486)              Stage III   (p=0.515)                                           Stage IV* 
 
Figure 34: Kaplan-Meyer survival curves of VEGFR-2 plasma membrane expression in colon and rectum, by stage.              
* no comparasion was realized, because all cases are VEGFR-2+
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                     Stage I   (p=0.803)                   Stage II   (p=0.352)             Stage III   (p=0.962)                                   Stage IV (p=0.852) 
 
 
 
 
 
 
 
 
 
                     Stage I   (p=0.428)                   Stage II   (p=0.186)            Stage III   (p=0.840)                                 Stage IV (p=0.047) 
 
Figure 35: Kaplan-Meyer survival curves of VEGFR-3 plasma membrane expression in colon and rectum, by stage. 
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Assessment of correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expressions and 
the clinical data revealed that VEGF-A positive cases were associated with “Patient gender” 
(p=0.016) and VEGF-C shows a tendency to  association with “Personal History of CRC” (p=0.060) 
(Table XXX). 
When analyzing correlation with data from diagnosis/surgery we find association between 
VEGF-C expression with “Tumour Localization” (p=0.037), and “Macroscopic Cancer type” 
(p=0.048). VEGFR-3 shows association with “Hepatic Metastasis” (p=0.032) (Table XXXI). 
When analyzing correlation with pathological data we find association between VEGF-A and 
VEGF-C expression and “Differentiation” (p=0.001 and p=0.007, respectively); VEGF-C expression 
and “Tumour penetration” (p=0.010); VEGFR-2 expression and “Histological type” (p=0.007) 
(Table XXXII). 
 
Observing colon and rectal cancer overall-survival curves assessed by log-rank test, of 
VEGFA, VEGFC, and VEGFR-2, VEGFR-3, Figure 32 – 35 we find a statistically significant 
association in VEGF-C expression and stage III for rectal cancer  (p=0.019) and VEGFR-3 expression 
and stage IV for rectal cancer  (p=0.047). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________5. DISCUSSION 
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5.1EPIDEMIOLOGICAL CHARACTERIZATION 
 
CRC epidemiological data abounds in the worldwide literature, but in the case of the 
Portuguese population this data are scarce and the existing studies are retrospective studies based 
on cancer registries but with few data that permits to characterize the affected population. 
In the developed world, CRC represents a major public health problem (321) and  in 
Portugal, it is the second most frequent cancer and the second cause of death by cancer (18,20).  
The North of Portugal is traditionally considered to be an area of high CRC incidence. Braga 
Hospital, in the North of Portugal, has an area of reference of 300000 patients, so with this first task 
we intended to characterize the patients treated at this hospital and also comparing the results with 
the literature data. In the future and with the extension to other regions this will permit a better 
adjustment of screening programs. Our results clearly demonstrated that CRC is a major problem of 
public health impact due to the high incidence and the degree of advanced stage of the tumours at 
moment of diagnosis. 
 
5.1.1 GENERAL CHARACTERIZATION 
5.1.1.1 AGE AND GENDER    
 
In this study most of the 672 patients, 419 (62.4%), were male patients and the age range 
of most patients (61%) was 61-80 years old. Except for the group older than 81 years old, CRC 
incidence was more frequent in men. Similar results were found in literature with CRC, being more 
frequent at advanced age and in men (1,3,4,14).   
Advanced age is the most significant risk factor for diagnosis of CRC which is defined as a 
disease of elderly people, with the majority of cases arising after 65-70 years of age and with an 
incidence relatively lower under 40 years. Still, 15% of cases will occur in people ≤ 50 years old 
(3,13,22,230,322–326), although another study suggests a lower value (7%) (327) and a large 
study identifies it as one of the 10 most commonly diagnosed cancers among men and women aged 
20-49 years (22). Early onset of CRC is assumed to be indicative of genetic susceptibility (323), 
often associated with a positive family history (328). In some studies, such younger patients  
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presented more advanced disease and more aggressive tumour grades at diagnosis and had less 
favourable prognosis (22,327,329). Also advanced CRC prevalence increases with age and is higher 
among men than women (21,321,326,329,330) and cross-sectional analyses estimated that men 
reach an equivalent prevalence at a much younger age than women (21). 
  
5.1.1.2 ANATOMIC DISTRIBUTION OF TUMOURS   
 
Among the 672 patients, colon cancer was more frequent than rectal cancer (65.3% versus 
34.7%) and most colon cancers were left-sided (64.7% of all colon cancers). In the case of rectal 
cancer most (50.6%, n=118) were localized in the middle third. Similar results are documented in 
literature (13,329,331–333). 
Tumour distribution throughout colon and rectum depends on genetic and environmental 
factors involved in colorectal carcinogenesis and on gender, race and patient´s age (13,329). In 
general, almost two-thirds of all bowel cancers are colon cancers and over one-third are rectal 
cancers (331–333). Recently, other studies reported a shift of CRC distribution to the right colon in 
the high risk population for unknown reasons  (334–338), and other have suggested that the 
frequency of right-sided colon cancer increases in elderly patients (13). This shift of CRC distribution 
implies that arguments used to recommend full colonoscopy instead of flexible sigmoidoscopy in 
CRC screening can be applied in high risk countries and that this is an issue that deserves further 
attention in future years, to document if that shift is also occurring in the population of Braga 
Hospital.  
 
5.1.1.3 PAST PERSONAL AND FAMILIAR HISTORY  
  
 Epidemiological studies suggest that at least 15% of colorectal cancers arise in individuals 
with an inherited predisposition for the disease (18,339). The literature also reveals that positive 
familiar story is strongly associated with CCR (13,326) although it is considered a high specific 
association with low sensitivity (326). 
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In our study, 94.8% of patients had no history of previous colorectal polyps; 4.1% of patients 
had a previous personal history of CRC; 7.7 % had a personal history of other cancers and 9.7% of 
patients had a positive familiar story for CRC.   
Knowing CRC natural history, we would expect a higher incidence of previous colorectal polyps 
history. This lower value could be the result of the low adherence of patients to colonoscopy without 
symptoms. Also the value of familiar story is underestimated since a significant number of patients 
do not know ignore their relative’s cause of death. 
  
5.1.1.4 CLINICAL PRESENTATION  
 
 Most patients (81.3%) from our study were symptomatic at diagnosis. Analysing colon and 
rectal cancer, 77.4% (n=340) and 88.5% (n=206), were symptomatic at diagnosis, respectively.  
Digestive bleeding was the most frequent symptom for both (17.1% and 20% respectively), followed 
by large bowel obstruction in colon cancer (15.0%) and digestive bleeding associated with change in 
bowel habits (17.4%) and change in bowel habits (14.5%)  in rectal cancer.  
Symptoms of CRC can be nonspecific or quite fulminant (340). Signs and symptoms of 
colon and rectal cancers are varied, nonspecific, and somewhat dependent on the localization of the 
tumour (48). Traditionally right-side colon cancers bleeds asymptomatic and are detected by anemia 
discovered by a routine haemoglobin determination or when studying constitutional symptoms. 
Cancers located in the left colon are often constrictive in nature, so patients more frequently notice a 
change in bowel habit. In rectal cancer, the most frequent symptom is hematochezia, other frequent 
symptoms are tenesmus and change in bowel habits (48). In a meta-analysis Jellema et al. (326) 
analysed various symptoms of CRC and concluded that the symptoms most commonly investigated 
included abdominal pain, rectal bleeding, change in bowel habits, and perianal symptoms. Of the 
typical symptoms of CRC, only weight loss had some diagnostic value, with a fairly high specificity 
(326).      
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5.1.2 OPERATIVE REPORTS BY SURGEONS 
 
Operative reports by surgeons like type of surgery, presence of perforation and tumour 
mobility were collected.  
Emergency situations are most commonly related to the complications of tumour 
obstruction (341) or tumour perforation (341,342), both with a poor prognosis and high risk of 
recurrence (341,343).  
Data from literature are variable regarding the emergency operation incidence, but overall 
approximately 20% of patients with colorectal cancer present as an emergency (343). Cuffy et al. 
(344) reported that over 15% of all cases with CRC present acutely as obstruction or perforation, 
with a mortality rate reaching 8.2% after an emergency operation. A lower value was documented by 
Lane Smothers et al. (345), 15.7% in a study with 184 CRC patients, and by Pavlidis et al. (346), 
12%, in a study realized with 1009 patients with CRC.   
In this study, 422 (96.1%) of colon and 203 (87.1%) of rectal cancer patients have been 
submitted to surgical treatment, and of this, 20.9% and 4.9%  have been submitted to a urgent 
operation, respectively. 
Perforation was more frequently associated with colon than rectal cancer (7.6% vs. 1.5%) 
and in both cases cancers were presented at laparotomy as mobile masses (82.2% and 66.9% 
respectively). 
 
5.1.3 HISTOPATHOLOGICAL REPORTS 
 
When pathologists examine a CRC specimen, they are taking a single fragment of the 
tumour at a given time, thereby providing information on the extent of tumour diffusion. A 
quantitative assessment of tumour extension, however, is insufficient to provide additional 
diagnostic, prognostic, and possibly predictive information required to plan the best therapeutic 
strategy (347).         
 Histopathological reports like tumour size, macroscopic serosal involvement, tumour 
differentiation, margin resection and blood and lymph node involvement was determined by two  
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experienced pathologists at Pathology Department of Braga Hospital. Some of these data will be 
reflected in the final pathological stage, pTNM. 
 
5.1.3.1 TUMOUR SIZE 
 
Most of the cancers analyzed, 49.0% of colon cancer and 52.7% of rectal cancer, have a 
maximum tumour diameter smaller than or equal to 4.5 cm. Tumour size should be reported as part 
of permanent record of tumour description. Although the size of the tumour is of no prognostic 
significance, it may be important for quality control of tumour size determined by nonpathologic 
means (eg, imaging modalities) (348).  
 
 5.1.3.2 MACROSCOPIC SEROSAL INVOLVEMENT  
 
Macroscopic serosal involvement corresponds to a pT3 in TNM classification; in our series, 
69.9% of colon cancers and 53.7% of rectal cancer, presented with macroscopic serosal 
involvement. When Macroscopic serosal involvement is present, even in the absence of lymph node 
involvement (AJCC/UICC stage IIB classification) it also identifies high-risk disease requiring 
adjuvant therapy (347,349,350). 
 
5.1.3.3 TUMOUR DIFFERENTIATION 
 
Tumour differentiation is consistently recognized as an important prognostic parameter 
(347,351). In our series, most of the cancers analysed were moderately-differentiated, 40.8% of 
colon cancer and 39.4% of rectal cancer.  
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 5.1.3.4 RESSECTION MARGINS INVOLVEMENT  
 
For colon cancer the primary determinant of the extent of bowel resection is the need for 
adequate removal of lymph nodes and arterial supply that is consistent with the creation of a well-
vascularized anastomosis. An adequate minimum length for proximal and distal colon resection 
margin is 5 cm, although they are generally much greater. Radial, non-peritonealized negative 
margins resection of the colon should be obtained and must be histologically free of disease to 
achieve a curative resection (352).  
For rectal cancer the primary determinant of the extent of resection of proximal rectum is 
determined by technical considerations for obtaining adequate lymphadenectomy and 
reconstruction. The margin resection length should be a minimum of 5 cm (352). The current 
recommendation for a adequate distal margin of resection is 2cm, and this is adequate for 
preventing local recurrence (353). In the case of the circumferential margin, 1 mm of margin is the 
current accepted margin, but if 2 mm were obtained instead of the 1 mm, local recurrences rates 
decreases from 16% to 5.8% (353). 
In our study we only observed “Margins resection involvement” in 6 patients of colon cancer 
and in 20 of rectal cancer patients.  
 
 5.1.3.5 VASCULAR INVASION 
 
In our study, it was reported 54.2% and 55.6% of venous vessel invasion and 39.3% and 
44.3 of lymphatic vessels invasion, for colon and rectal cancer, respectively. 
CRC exploits the lymphatic and venous drainage sistem for dissemination to regional lymph 
nodes and distant organs and vascular invasion is an independent adverse prognostic factor in CRC 
(347,354,355). The diagnosis of vascular invasion in CRC specimens may be exceedingly difficult 
with conventional hematoxylin-eosin staining alone (356). Literature data reported a CRC vascular 
invasion in ranges from 10% to 89% (355) most likely due to the different criteria used for its 
identification or because of patient selection. To note that in some studies no distinction was made 
between venous and lymphatic vessels or intramural and extramural venous invasion (347).  
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 5.1.3.6 HISTOLOGICAL STAGING AND FOLLOW-UP 
 
 Stage at diagnosis plays a significant role in CRC survival (15,254,324–326,340,357) and 
is actually the main prognostic factor in CRC (3,15,235,324,325) but it is difficult to accurately 
determine the stage prior to surgical treatment (358). 
 Staging has evolved over time, and TNM system is used currently. This is an evaluation 
system based on 3 variables: primary tumour (T), regional nodes (N), and metastasis (M) (340,359). 
In the past, patients presenting the same stage of CRC were considered similar in terms of 
prognosis. The new staging criteria recognize that they are usually quite different and subsets of 
patients with varying survival statistics can be found (340,358). Less than one quarter of the 
patients present early disease (Stage I) that is curable by surgical resection (15,324,340) and more 
than 20% of CRC patients present stage IV disease at diagnosis (340). This has an impact in five 
year survival rates and we can expect a five-year survival rate greater than 90% for stage I 
(15,324,326) and less than 10% for stage IV (326). On the other hand, around 40% of patients 
diagnosed with CRC eventually develop metastatic disease (325) and about two-thirds of the patients 
undergo resection with curative intent, but 50% of patients still die of the disease within five years 
(357,360).            
  As we stated above, most colon and rectal cancer patients from our study were stage IIA 
(33.7% ans 21.2%, respectively), followed by stage IIIB (22.5%) for colon cancer patients and stage 
IV (18.2%) for rectal cancer patients.  
Despite expecting a worse prognosis in rectal cancer patients, we observed that 27.8% of 
colon cancer and 18.0% of rectal cancer patients died from a colorectal cancer-related cause. 
Follow-up time ranged from 2 to 7 years and in that period 14.6% of patients with colon cancer and 
19.3% with rectal cancer had recurrence, mostly in liver. 
These data are consistent with the literature (15,324,340), with low percentage of patients 
diagnosed at stage I, 13.0% for colon cancer and 18.7% for rectal cancer. Also, the percentage of 
stage VI diagnosed patients was very close to that observed in literature, with 18.2% for rectal cancer 
and 18.7% for colon cancer (340). From these data, we would expect a higher mortality in rectal 
cancer patients compared to colon cancer, but we observed very similar results, documented by the  
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log-rank test, when comparing between colon and rectum cancer survival (p=0.518). In the 
literature, studies have shown conflicting results when comparing prognosis and localization (360). 
Reduced survival in left colon cancer compared to right colon was reported in a Norwegian study 
from 1987 and Aldrige et al. (360–362) reported similar results, but no differences were detected in 
other studies (360,363–365). We also observed a lower value of 5 years disease recurrence, 14.6 % 
and 19.3% for colon and rectal cancer respectively, when compared with values of 40% found in the 
literature. These data may reveal a different biological behaviour or be the result of the follow-up 
time, however, other studies with larger series must be done. 
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5.2 MCTS, CHAPERONES AND GLYCOLYTIC METABOLIC MARKERS 
IMMUNOHISTOCHEMICAL EXPRESSION IN CRCS AND NORMAL ADJACENT TISSUES AND 
CORRELATION WITH EPIDEMIOLOGICAL DATA 
 
Our group has previously analyzed the expressions of MCT1, 2, and 4 in a series of 126 
CRC (109) and we document that the expression of the MCT isoforms in tumour cells was 
significantly increased when compared to normal adjacent epithelium and we also observe a 
significant gain in membrane expression for MCT1 and MCT4 and loss of plasma membrane 
expression for MCT2 in tumour cells (109).  
With this work we hypothesize to reinforce the results obtained, by evaluating MCT1, MCT4 
immunohistochemical expression in this larger series of 580 cases, adding immunohistochemical 
expression evaluation of chaperones CD147, CD44 and glycolytic metabolic marker GLUT1 and 
correlation with MCTs expression to further understand the role of MCTs in CRC glycolytic 
metabolism, besides the advantage of the correlation with epidemiological data.  
 In this study, we evaluated MCT1, MCT4, CD147, CD44 and GLUT1 immunohistochemical 
expression in a CRC series of 580 cases and we observed that all the proteins studied are 
overexpressed in tumours when comparing with normal-adjacent tissue and in plasma membrane 
expression pattern (p<0.001). MCTs were the proteins most frequently expressed, followed by 
CD147, GLUT1 and CD44. 
MCT1 results are consistent with the previous results of our group (104,109), also 
documented by Koukourakis et al. (115) who document a strong membranous expression in cancer 
cells of CRC but not in the adjacent stroma or the normal colonic mucosa. 
Similar results were obtained with MCT4, we observed that MCT4 expression and plasma 
membrane staining was higher in tumour cells than in normal adjacent cells. These results are 
consistent with the previous results of our group (104,109), although Koukourakis et al. (115) and 
Lambert et al. (144), observed only a weakly and no expression of MCT4 in tumour cells, 
respectively, suggesting a minimal role in the metabolic intratumoural communication (115).  
As stated before, cancer is associated with an increase in glycolytic flux (102,108–
110,112,122) with consequent increase in lactic acid production (103,109–112). The maintenance 
of intracellular pH is achieved by upregulation of MCTs (109) namely; MCT1 with a ubiquitous tissue  
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expression (109,127) and participating in the bidirectional transmembrane exchange of lactic acid 
(115) and MCT4 with a localization more restricted to the glycolytic cells (109,366) and with a low-
affinity lactate (105,124,138,366). So we might predict that its expression would increase in CRC 
cell to enable to export the increased quantities of lactic acid and so prevent apoptosis. 
The lower expression in normal adjacent cells is in accordance to what is known on normal 
colon metabolism. MCTs were demonstrated to transport aliphatic monocarboxylates, including 
lactate, pyruvate and ketone bodies but also the branched-chain oxo acids derived from leucine, 
valine and isoleucine, and the ketone bodies acetoacetate, β-hydroxybutyrate and acetate (134,135); 
consequently, MCTs play a pivotal role in mammalian metabolism. We also observed that expression 
in normal adjacent cells is more marked for MCT1, what is in accordance to the broader distribution 
of this transporter and also because it transports butyrate, a substrate for colonic epithelial cells, 
and possess trophic effects in the colon (127,134,135,137). 
Chaperones CD147 and CD44 immunohistochemical expression were also overexpressed in 
CRC when comparing with normal adjacent tissue and in plasma membrane expression pattern 
(p<0.001). Functional expression of MCTs is regulated by these accessory proteins (104,135,157–
162), that are involved in trafficking,  anchoring of plasma membrane proteins (135) and 
communication of cell-matrix interactions (181,182), respectively. 
With regard to CD147, besides acting as MCT chaperone, CD147 expression seems to be 
dependent on MCT1 and MCT4 expressions (135,157,160)  and in all tissues expressing MCT1 or 
MCT4, CD147 expression was consistently found co-localized in the same regions (158). In our 
study, we observed a higher expression and higher plasma membrane staining was in tumour cells 
than in normal adjacent cells. These results are consistent with those observed in the literature. 
Zheng et al. (177), Buergy et al. (178) and Jin et al. (179) documented that CD147 expression is 
stronger in C and metastatic carcinoma than normal adjacent cells.  
The glycolytic metabolic marker GLUT1 has also a higher expression and higher plasma 
membrane staining in tumour cells than in normal adjacent cells. These results were expected 
because as a consequence of the high energetic demands observed in CRC, increased glucose 
metabolism and utilization is accomplished by upregulation of glucose transport across the plasma 
membrane (209,212),  so increased GLUT1 expression reflects an increased glycolytic metabolism 
(209,210,212,213,215,367) in CRC. 
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Some studies suggest that GLUT1 expression may play an important role in the survival of 
tumour cells by promoting an adequate energy supply (210,213) and  could be a useful biomarker 
for malignant transformation (210,214,216). 
We studied the association between MCT isoforms and the remaining proteins and observed 
that in tumour samples, MCT1 positive cases were associated with CD147 plasma membrane 
expression and between MCT4 and both chaperones and GLUT1 plasma membrane expression. As 
stated before, functional expression of MCTs is regulated by these chaperones (104,135,157–162) 
and our results support these previously mentioned findings. Also the association found between 
MCT4 and the glycolytic metabolic marker GLUT1 can result from the fact that CRC cells upregulate 
GLUT1 to increase glucose uptake and, subsequent to “aerobic glycolysis”, while the accumulated 
lactate is extruded by MCTs.  
We studied the association between MCT chaperones, metabolic marker GLUT1 expression 
and clinical data, diagnosis/pre-operative staging data pathological and follow-up data and 
compared with other cancer literature data on CRC. 
MCT1 positive cases were associated with the presence of “Pulmonary Metastasis” so more 
advanced CRC stage. In our previous study we documented a significant correlation between MCT1 
plasma membrane staining and vascular invasion (109), that was not observed in this larger series, 
one possible explanation is that different methods may be used to evaluate vascular invasion. 
We found that MCT4 positive cases were associated with “Personal History of CRC”. 
Patients with a “Personal History of CRC” presented an increased risk to develop CRC, this higher 
expression of MCT4 in the patients may reflect an alteration of CRC metabolic profile conferred in 
the previous cancer. 
There was also an association between MCT4 positivity and “Rectal Examination”, namely 
with fixed rectal cancer. With digital rectal exam, the size, location, and degree of fixation of most low 
and some middle third rectal tumours can be detected and assessed. Assessment of the extent of 
local disease by digital rectal exam is imprecise (368,369), however, rectal fixed tumours are 
generally associated with an advanced rectal cancer stage (369). 
There is some controversy in the literature when analyzing the correlation between CD147 
expression and the clinicopathological characteristics in CRC. In our study, we only found 
association between CD147 positivity and “Tumour Size” and a tendency to associate with “Patient  
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Age” (p=0.056), also observed for MCT4 plasma membrane positive cases (p=0.052).   
 Zheng et al. (370) reported that CD147 expression was positively correlated with tumour 
size, depth of invasion, vascular or lymphatic invasion, grade of infiltration of CRC. On the other side, 
Jin et al. (167) documented a CD147 overexpression in CRC compared to normal mucosa, but no 
correlation was found with TNM stage. Also  Jung et al. (149) and Stenzinger et al. (371) showed 
that the CD147 overexpression was not associated with clinicopathological parameters, although 
Stenzinger et al. (371) and Buergy et al. (372) observed that it was associated with a poor clinical 
prognosis. 
 Associations of CD147 expression with survival and prognosis have been suggested for 
other tumours, such as endometrial (373), ovarian carcinoma (173) and esophageal squamous cell 
carcinomas (374) although in esophageal squamous cell carcinomas Ishibashi et al. (176) it was 
reported that CD147 expression was not associated with the recurrence-free survival. In oral 
squamous cell carcinoma, increased expression of CD147 has been shown to correlate with 
lymphatic metastasis and tumour progression (375)  and Yang et al. (376) found that CD147 
expression in breast carcinoma cells rendered them resistant to anoikis, a form of apoptosis 
triggered by a lack of improper cell-matrix interactions, through an MAP kinase-dependent pathway. 
Marieb et al. (148) documented that upregulated CD147 expression stimulates hyaluronan 
production by elevating hyoluronan synthases, which is closely related to the anchorage-independent 
growth of cancer cells. Taken together, our result supported the opinion that CD147 might enhance 
tumour growth of CRC by disrupting the balance between apoptosis and proliferation. 
In our study, we only documented a correlation of CD44 immunoexpression and “Vessel 
Invasion” in other words with metastatic spread also documented in the tendency to associate with 
“Hepatic Metastasis” (p=0.055). These results are in harmony with previous reports, which states 
that extracellular acidification induces invasion. 
Several studies have suggested an important biological role for CD44 in tumour progression 
and metastasis, and the potential for the use of CD44 variant expression as a clinicopathological 
marker of disease progression in CRC (189–194) and other cancers (195–199). Some studies 
observe that protein expression of standard and variant isoforms of CD44 correlates with a poor 
prognosis in CRC (200–202) and that it can be a molecular marker for CRC and its micrometastasis 
to the regional normal lymph node (202), but divergent conclusions have been reached regarding a  
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potential relationship between variant CD44 expression and the prognosis of patients with CRC 
(181,203–205). More recent studies suggest either no role for CD44s or a worse clinical outcome 
(192,206–208), documented by correlation between CD44 expression and metastatic spread and 
survival (377–380). 
Also studies performed in gastric cancer found no correlation of CD44 immunoexpression 
and clinicopathological characteristics such as tumour size, pathologic stage, histological grade, 
angioinvasion, perineural invasion and lymph node metastasis or prognosis in terms of survival 
(183,381). However, Ghaffarzadehgan et al. (377) reported significant correlation between CD44 
expression and histological grade and patient survival. 
GLUT1 positive cases in plasma membrane show a significant association with 
“Macroscopic Cancer type”, namely with exofitic lesions, high CEA level (p=0.05) presence of 
“Hepatic Metastasis” (p=0.046), “Tumour Differentiation” (p=0.009), and a tendency for association 
with “Spread to nearby lymph nodes” (p=0.058) namely poorly-differentiated tumours, in other 
words, tumour characteristics associated with more aggressive tumours and poor prognosis, so 
tumours with high energetic demands to grow and metastize. Previous studies suggest that GLUT1 
expression may play an important role in the survival of tumour cells by promoting an adequate 
energy supply (210,213) and could be a useful biomarker for malignant transformation 
(210,214,216). Many studies have reported a correlation between GLUT1 expression level and the 
grade of tumour aggressiveness (209,212,213,217,218), increased proliferative activity and energy 
requirements (212) which suggests that GLUT1 expression may be of prognostic significance 
(209,213,219).  
In our study, we documented a significant correlation between GLUT1 and tumour 
differentiation, results which are in accordance with those of Sakashita et al. (382) that reported that 
GLUT1 expression was significantly different between well differentiated and less differentiated 
groups in CRC. Also, Ito et al. (383) in lung adenocarcinomas and Chen et al. (384) in breast 
cancer, demonstrated that GLUT1 immunostaining was stronger in tumours with lower 
differentiation.  Others studies (214,217) reported that there was no correlation between GLUT1 
expression and histological differentiation.   
 The relationship between GLUT1 expression the depth of invasion has been reported in 
CRC. Sakashita et al. (382) reported that GLUT1 expression was significantly different between T1  
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and T2 groups, however, Younes et al. (217) and Young Jin Jun et al. (213), demonstrated that 
there was no significant difference between GLUT1 expression and depth of invasion. Younes et al. 
(217), Young Jin Jun et al. (213) and Zhou et al. (218) documented that there was a close 
correlation between strong GLUT1 expression and the frequency of lymph node metastasis in CRC. 
Sakashita et al. (382) reported that the correlation of GLUT1 expression in CRC with nodal 
metastasis was higher than that in those without, but the difference was not significant. In our study, 
we did not observe that correlation but we documented a significantly correlation between “CEA 
level” and “Hepatic metastization” both associated with more advanced cancers. The greater degree 
of GLUT1 expression in these tumors indicates that GLUT1 may be important for maintaining the 
high-energy requirements of aggressive cancers. 
 Young Jin Jun et al. (213) documented that there was a close correlation between GLUT1 
expression and tumour stage, and also showed that GLUT1 expression was significantly correlated 
with poor overall survival and disease-free survival. Also Shen et al. (219) found a worse prognosis in 
GLUT1 positive cancers; but Haber et al. (214) reported a association of GLUT1 staining status and 
stage; however, no statistical significance was revealed. In our study we did not observe any 
statistically significant relation with survival. Also Hong et al. (210) did not show these results, but 
suggest the possibility that tumours with absent GLUT1 staining might express another GLUT iso-
form, which might be associated with poor prognosis (210,385). Also, for breast cancer, Avril et al. 
(386) find no association. On the other hand, other studies reported that GLUT1 correlates with poor 
prognosis and tumour aggressiveness in carcinomas of the lung (387,388) and bladder (389), and 
in squamous cell carcinoma of the head and neck (390,391) and in ovarian cancer (392,393). 
Although the associations between MCTs, chaperones and GLUT1 and clinicopathological 
data associated with worse prognosis, when we observe colon and rectal cancer survival curves 
assessed by log-rank test, we only find a statistically significant association between MCT1 
expression and stage IV for colon cancer; GLUT1 expression and stage I for rectal cancer and a 
tendency to association between MCT4 expression and stage III for colon cancer  (p=0.060); thus 
suggesting that longer follow-up times may be necessary to document this relationship. 
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5.3 MCTS, CHAPERONES AND GLYCOLYTIC METABOLIC MARKERS 
IMMUNOHISTOCHEMICAL EXPRESSION IN COLORECTAL CANCER HEPATIC METASTASIS AND 
NORMAL ADJACENT TISSUES AND CORRELATION WITH EPIDEMIOLOGICAL DATA 
 
Our initial aim was to correlate the results of MCTs, chaperones and Glycolytic Metabolic 
Markers Immunohistochemical expression in Colorectal Cancer Hepatic Metastasis with the results 
obtained in CRC and ascertain if the metabolic profile observed in CRC was maintained in CRC 
Hepatic Metastasis, but due to the few number of patients that have been submitted to hepatic 
resection during this period this was not possible.  
So we retrieved a new series with 45 patients that have been submitted to CRC hepatic 
metastasis resection in the period of 1 January 2003 to 1 de January 2011 and analyzed the 
expression of MCT4, CD147, CD44 and GLUT1 in CRC hepatic metastasis and normal adjacent 
tissue.  
No data are available in literature about this issue, being this the first work performed with 
these proteins in CRC hepatic metastasis. 
 When analyzing CRC hepatic metastasis, the same expression patterns were observed in 
tumour positive cases, in immunoreaction and plasma membrane suggesting the same alterations 
in metabolic profile documented in CRC tissues. The lower significance observed in the metastases 
series may be justified by the lower number of cases. 
Analyzing the associations between MCT4 and the other proteins we observed that MCT4 
positive cases were associated with both chaperones and GLUT1 plasma membrane expression, as 
observed in CRC tissues, reinforcing the role of the chaperones in the function of MCT4 
(104,135,157–162) and upregulation of GLUT1 to increase glucose uptake and, subsequent to 
“aerobic glycolysis”.  
Assessment with anatomopathological data from primary tumour and Hepatic metastasis, 
revealed CD147 positive cases were associated with “Venous Vessel Invasion” (p=0.042) and no 
other correlation was observed, perhaps because of the series size.  
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5.4 VEGF-A, VEGF-C, VEGFR-2 AND VEGFR-3 IMMUNOHISTOCHEMICAL 
EXPRESSION IN CRCS AND NORMAL ADJACENT TISSUES AND CORRELATION WITH 
EPIDEMIOLOGICAL DATA 
 
Tumour angiogenesis is essential to allow neoplastic mass development favoring access to 
the blood components, and also strengthening the vascular routes in the metastatic process 
(4,241,242,244,247,248). Neovascularisation promotes tumour growth by supplying nutrients, 
oxygen and releasing growth factors that promote tumour cell proliferation (232,239,244,249,250).
 Numerous studies have demonstrated that tumour overexpression of VEGF is associated 
with advanced tumour stage or tumour invasiveness in various common human cancers 
(232,240,394,395) and, its overexpression in colon cancer tissue indicates poor prognosis (395); 
although paradoxically, some data showed that VEGF has not a significant prognostic value in colon 
cancer tissue (396).         
 Our results corroborate the premises that angiogenesis plays a key role in tumourigenesis 
and metastatic processes (231,232,397), because all the markers involved with neovascularisation 
were consistently expressed in tumour cells. Additionally, VEGF-C, a lymphangiogenic maker, was 
more significantly expressed in cancer cells rather than in normal cells. This general view of our 
results clearly indicate that CRC are predominantly composed by cancer cell that are directly or 
indirectly associated to the high expression of molecular players related to the blood angiogenesis 
and that the major lymphangiogenic molecule is also more importantly expressed in cancer cells 
that primarily escape from primary site to metastatic route by lymphatic vessels.    
 Normally, VEGF family members are weakly expressed in a wide variety of human and 
animal tissues; however, high levels of VEGF expression can be detected at sites where physiologic 
angiogenesis is required, such as fetal tissue or placenta, or in the vast majority of human tumours 
and other diseases such as, chronic inflammatory disorders, diabetes mellitus, and ischemic heart 
disease (4). Furthermore, VEGF family and its receptors are expressed at high levels in metastatic 
human colon carcinomas and in tumour-associated endothelial cells, respectively (4,240). 
Consequently, VEGF is recognized as a prominent angiogenic factor in colon carcinoma and the 
assessment of VEGF expression may be useful for predicting metastasis from CRC (4,240).  
 In literature, the role of the VEGF family members in CRC has, to date, mainly concentrated  
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on VEGF-A, but the newer members of the family, VEGF-C and VEGF-D, may have important roles to 
play in both angiogenesis and lymphangiogenesis (398).      
 VEGF-A promotes angiogenesis through enhancement of permeability, activation, survival, 
migration, invasion, and proliferation of endothelial cells (4,399) and play a role in early tumour 
development at the stage of adenoma formation (4,12,400) and some studies document a 
overexpression of VEGF-A in CRC (4,401). In other studies, VEGF-A expression was also found to be 
higher in patients with metastatic tumours (4,240,243), and high levels of VEGF-A expression were 
associated with advanced cancer stage and related with unfavorable prognosis (4,395,396,402). 
VEGF-A was documented as a useful marker for prognosis by significantly correlating with angio-
lymphatic invasion, lymph node status and depth of invasion, notwithstanding it was not an 
independent prognostic factor (4,244,401).       
 VEGF-C gene was also found to be poorly and at maximum moderately expressed in CRCs 
when compared to control tissue (398,403); however, the number of samples analysed in this study, 
particularly, was small (n=12). In a larger series, however, the immunohistochemical expression of 
VEGF-C was correlated with lymph node spread (398,404). In our study, in opposite to that observed 
in literature, we did not observe a statistically positive correlation between tumour and normal 
adjacent tissues of VEGF-A expression. The majority of the normal-looking tissues were strongly 
decorated by the VEGF-A reaction. On the other hand, we observed that VEGF-C was overexpressed 
in tumours when comparing tumour cell strongly decorated to the weak staining of the normal-
adjacent tissue (p=0.004).        
 The effect of VEGF depends not only on tumour cell expression of VEGF, but also on the 
VEGF receptors in the endothelial cells (4,232) so we also analyzed the associations between VEGF-
A, VEGF-C and the receptors VEGFR-2, VEGFR-3 expression in CRC tissues and we observed that in 
tumour samples,  VEGF-C positive cases were associated with VEGFR-3 expression (p=0.047), this is 
consistent with the fact that lymphangiogenesis induced by VEGF-C is driven mainly by the activation 
of the tyrosine kinase-linked receptor VEGFR-3 (405) and supports the fact that CRC escapes 
through lymphatic vessels, although no correlation with pathological data of lymph node metastasis 
or lymphatic vessel invasion was observed.      
 The comparison of the correlation among VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 
expressions and the clinical-pathological data, data from diagnosis/surgery and pathological data  
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revealed that VEGF-A positive cases were associated with “Patient Gender” (p=0.016) and “Tumour 
Differentiation” (p=0.001); VEGF-C expression with “Tumour Localization” (p=0.037), and 
Macroscopic Cancer type” (p=0.048), “Tumour Differentiation” (p=0.007) and “Tumour 
penetration” (p=0.010); VEGFR-2 shows association with Histological type” (p=0.007) and VEGFR-3 
shows with “Hepatic Metastasis” (p=0.032). All this characteristics characterize a high expression of 
molecules that contribute for progression, invasion and metastasis and poorer survival and 
prognosis that we observe in overall-survival curves for rectal cancer in VEGF-C stage III (p=0.019) 
and VEGFR-3 expression stage IV (p=0.047). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________6. CONCLUDING REMARKS/ FUTURE PERSPECTIVES 
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6.1 EPIDEMIOLOGICAL DATA 
As previously mentioned, the beginning of this thesis coincided with the creation of the 
Coloproctology Unit of Braga Hospital, responsible, among others diseases, by the treatment of 
patients with diagnosis of CRC. All the work was performed looking for the development of protocols 
as well estimulate multidisciplinary meetings with Surgery, Pathology and Oncology. Besides been 
necessary to the drawing of this thesis, this initiative also, allowed to standardize the diagnosis, 
staging, treatment and follow-up, leading to a significant improvement in the management of these 
patients.          
 As stated before, CRC epidemiological data are scarce in Portugal, and our results clearly 
demonstrated that CRC is a major problem of public health, impact due to the incidence and the 
degree of advanced stage of the tumors at the moment of diagnosis. This work not only allowed a 
better knowledge of our population, but with other parallel studies, improved patient treatment at 
Coloproctology Unit of Braga Hospital.       
 The majority of our results are consistent to that observed in the literature. Most of our CRC 
patients were male and old patients, reinforcing the role of these data in CRC risk factors. Most of 
our cancers were located in colon more precisely left-sided colon. From these data, it would be 
expectable that flexible sigmoidoscopy would be a diagnostic procedure sufficient for most cases of 
CRC, but most cancers of our series were diagnosed by total colonoscopy, resulting in part from the 
fact that most of these patients have not done a screening exam but as investigation of some 
symptom, as documented by the higher percentage of symptomatic patients at diagnosis in our 
series.  The low adhesion of our population to the CRC screening programs was also documented by 
the lower incidence of previous history of colorectal polyps, of previous personal and of a positive 
familiar story for CRC, than that observed in the literature.    
 As a measure of the re-structuring of Gastroenterology department of Braga Hospital and in 
part as a result of these observations, actually an annual screening programme is realized at the 
Braga Hospital.          
 From the reports collected from surgeons, we documented that most patients were 
submitted to a scheduled surgery, presenting similar results to that observed in the literature for 
emergent surgeries, what is associated to a worse prognosis as it influences staging besides the  
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patients being operated without a complete pre-operative staging.    
 Data from pathological reports reveals that although most of CRC in our series were small 
tumours, most of those tumours present macroscopic serosa involvement at diagnosis, what reflects 
a more advanced stage.         
 When analysing “Resection Margin involvement”, we documented that this was more 
frequent in rectal than colon cancer. This data was expectable not only resulting from anatomical 
surgical reasons but also from technical reasons. This reflects the higher percentage of patients with 
local rectal cancer recurrence compared to colon cancer patients.     
 In what concerns “Vascular Invasion”, venous vessel and lymph vessel are two routes of 
CRC metastization and actually considered as an independent risk factor. These data, and also the 
number of positive lymph nodes were not described in all specimens. For this reason we intend, with 
the Pathological department, and as it was already done for other cancers, to standardize the 
histological report of colon and rectal cancers.       
 Also, the results of “Staging at Diagnosis” were similar to that observed in the literature, 
with few patients diagnosed at stage I and almost 19% at stage IV, for rectal and colon cancer. 
“Metastization/Recurrence” during the follow-up were more frequent in rectal than colon cancer 
patients, but in both this was more frequent in the liver and most patients were asymptomatic, 
reinforcing the need of periodical follow-up. Despite expecting a worse prognosis in rectal cancer this 
fact was not documented in survival curves and longer follow-up may be necessary. 
 
 
 
The results presented in this chapter were submitted for publication in international 
periodicals: 
 
- Martins SF, Reis RM, Amorim R, Pinheiro C, Rodrigues AM, Baltazar F, Filho AL. An epidemiologic 
descriptive study of Colorectal Cancer patients treated at Braga Hospital, Northern Portugal. 
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Other results collected in CRC prospective database were used as material for Master 
thesis of medical students and some were posteriorly published: 
 
. “Assessment of Quality of life (QoL) after rectal cancer surgery.” 
 
- Supervisor of Master thesis presented at School of Health Sciences in January 2009. 
 
. “Sensibilidade da Ecografia Endorectal no estadiamento do Cancro do Recto: correlação com o 
estadiamento patológico.” 
 
- Supervisor of Master thesis presented at School of Health Sciences in January 2010. 
- Carriço L, Martins SF. Sensibilidade da Ecografia Endorectal no estadiamento do 
Cancro do Recto: correlação com o estadiamento patológico. Rev bras Coloproct, 
2011;30(4): 430-439. (Appendix 9) 
 
. “Evaluation of quality parameters of rectal cancer surgery at the Coloproctology Unit of Hospital de 
Braga.”   
 
- Supervisor of Master thesis presented at School of Health Sciences in January 2011. 
- Castro M, Martins SF.  Evaluation of quality parameters of rectal cancer surgery at the 
Coloproctology Unit of Hospital de Braga.  J Coloproctol, 2011;31(4): 362-371. 
(Appendix 10) 
 
 
. “Assessment of surgical risk in CRC patients: possum vs. Acpgbi?” 
 
- Presented as communication at “Congresso Nacional de Cirurgia 2012”  
- Accepted for publication at Revista Portuguesa de Cirurgia. Goulart A, Martins SF. 
Assessment of surgical risk in colo-rectal cancer patients: possum vs. Acpgbi? 
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6.2 CRC AND HEPATIC METASTASIS METABOLIC MARKERS  
 
One of cancer features is the ability to maintain a sustained proliferative signaling, that is 
responsible for the faster tumor growth comparing to normal cells. Thus, tumor cells present higher 
energy requirements, and this enhanced glucose consumption and glycolytic metabolism results in 
the production of high amounts of lactic acid. Therefore, in order to survive, cancer cells must 
reprogram their energy metabolism. 
Recently, much attention has being given to the manipulation of tumour metabolism, in the 
context of therapeutic approaches and the expression of MCTs have already been documented by 
several authors (including our group), in CRC and other cancers. 
The purpose of this work was not only to reinforce our previous results with a smaller series 
but also to expand the study to other metabolic markers, namely chaperones CD147, CD44 and the 
glycolytic metabolic marker GLUT1 to further understand the role of MCTs in CRC glycolytic 
metabolism, besides the advantage of the possibility of correlation with epidemiological patients’ 
data.  
Moreover, as well known, metastization is one of the main prognostic factors, so, apart from 
evaluating these metabolic markers in the primary cancer (CRC), we evaluated the same proteins in 
a seires of CRC Hepatic Metastasis, for which there is no data in the literature.   
 As stated before in the present study, it was demonstrated that MCT1, MCT4, CD147, CD44 
and GLUT1 are overexpressed in human CRC samples, when compared with normal adjacent 
tissues. As expected, up-regulation of GLUT-1 is a result of the high energetic demands of CRC cells 
to promote an adequate energy supply. This, in turn, results in an increased lactic acid production, 
thus the up-regulation of MCTs is an expected result in order to maintain intracellular pH and 
prevent apoptosis.  
Observing those results, we also documented that the expression of these metabolic 
markers in normal adjacent cells was more pronounced for MCT1 than the remaining proteins. This 
can reflect the influence of the tumor microenvironment, since the tissue evaluated is adjacent to 
the tumour, and may be under “tumour influence”. However, it could also reflect the broader 
distribution of MCT1 as well the function of butyrate transport, a substrate for colonic epithelial cells, 
which possess trophic effects in the colon. 
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To overcome this limitation, evaluation of theses markers in normal colic epithelium may be 
necessary although it was not possible. This must be taken into account when we think of MCTs as 
potential therapeutic targets, making MCT4, chaperones and GLUT1 more attractive, since their 
lower expression in normal adjacent tissue will be associated to fewer side effects.  
 When analyzing CRC Hepatic Metastasis series, the same expression patterns were 
observed in tumour positive cases, suggesting that Hepatic Metastasis hold the same alterations in 
metabolic profile documented in CRC tissues. In CRC Hepatic Metastasis, the results observed in 
normal adjacent cells were still more promising, comparing to CRC, as no expression was observed 
for MCT4, CD44 and GLUT1 in normal adjacent tissue, but once again the evaluation in normal 
hepatic tissue and in a larger series will be important.    
When we analyzed the association between MCT expression with chaperones, CD147 and 
CD44, and with GLUT1 in CRC and CRC Hepatic Metastasis as expected, by the reasons previously 
mentioned, we observed that in tumour samples MCT1 positive cases were associated with CD147 
plasma membrane expression and MCT4 with both chaperones (plasma membrane expression) and 
GLUT1. Further, in this evaluation, CRC Hepatic Metastasis holds the same alterations in metabolic 
profile documented in CRC tissues for MCT4.      
 When analyzing the correlation between plasma membrane expression and epidemiological 
data, the association of these proteins with characteristics as: “Age”, “Personal History of CRC”, 
“Rectal examination”, Macroscopic cancer type”, “Tumour size”, “Vessel invasion” and presence of 
Hepatic metastasis” and “Pulmonary metastasis”, we documented that the association with these 
parameters that reflect a worse prognosis, reflects the metabolic advantage that these tumor cells 
have acquired. Analyzing these correlations in the Hepatic Metastasis series, no association was 
observed, being the small series and the retrospective access to the data possible limiting factors. 
 
 
The results presented in this chapter were submitted for publication in international 
periodicals: 
 
Martins SF, Amorim R, Pereira H , Pinheiro C, Pardal F, Rodrigues AM, Preto A, Filho AL, Baltazar F. 
Monocarboxylate Transporters (MCTs) as rational therapeutic targets in Colorectal Cancer. 
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Other results presented in this chapter were used as material for Master thesis of 
medical students: 
 
. “Avaliação da expressão dos transportadores de monocarboxilatos nas metástases hepáticas do 
carcinoma Colorrectal” 
 
- Supervisor of Master thesis presented at School of Health Sciences in January 2012. 
 
 
Candidate to “Grande Prémio Fundação AstraZeneca 2008”: 
 
 “Expression of monocarboxylase transporters in colorectal carcinomas”. PI: Sandra Martins.   
 
 
Candidate to “Concurso FCT 2012”: 
 
“Papel dos transportadores de monocarboxilatos (MCTs) na comunicação entre a sinalização 
oncogénica e a remodelação metabólica em Carcinoma Colorrectal”. PI: Fátima Baltazar.  
 
Candidate to “Concurso FCT/CAPES 2012”: 
 
“Avaliação da crosstalk entre o metabolismo tumoral e a sinalização oncogénica: papel dos 
transportadores de monocarboxilatos (MCTs)”. PI: Fátima Baltazar.  
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6.3 CRC ANGIOGENIC MARKERS  
 
Angiogenesis is a key process for tumor growth and metastization. This study had as 
purpose to evaluate the expression of VEGF-A, -C and the receptors -2 and -3 in this large series of 
CRC and assess, if possible, correlations with clinicopathological data and impact on prognostic. 
Assessing the expression of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 in this series, we 
documented that all these markers were overexpressed in human CRC samples which suggest their 
role in tumour development and progression, by enabling new routes of oxygenation and nutrition of 
tumour cells, preventing tumour cell apoptosis.  
 When we compared CRC tissue and normal adjacent tissue we observed a statistically 
significant correlation for VEGF-C; a marker for lymphatic vessels, and its upregulation in the tumour 
tissue support the fact that lymphatic system is an escape route for metastization in CRC. We also 
observed a tendency for correlation with VEGFR-2, a receptor for the ligands VEGF-A and VEGF-C 
with action in terms of angiogenesis and lymphangenesis, contributing not only to tumour growth but 
also to tumour metastization. Observing the results of the expression of these markers in normal 
adjacent tissue, we observed that the staining was less pronounced for VEGFR-3 than the remaining, 
although present. This can reflect the biology of the tumor microenvironment, once the tissue 
evaluated is the normal-like adjacent tissue to the tumor, so it may be under the same “tumour 
influence”.  
To overcome this study limitation, evaluation of these markers in normal colonic epithelium 
may be necessary although it was not currently possible. When we analyzed the association between 
VEGF-A and -C and the receptor VEGFR-2, VEGFR-3 we observed that in tumour samples, VEGF-C 
positive cases were associated with VEGFR-3 expression. This is consistent with the fact that 
lymphangiogenesis induced by VEGF-C is driven mainly by the activation of the tyrosine kinase-linked 
receptor-3, VEGFR-3, and once again supports the fact that CRC escapes through lymphatic vessels. 
 When we evaluated the correlation of these markers with epidemiological data, we expected 
to find some particular associations namely with tumour size, vessel invasion and lymph node 
metastasis.  Although these associations were not found, correlations were observed with data that 
demonstrate tumour progression, in specifically with the fact of VEGF-A correlates with “Tumour 
Differentiation”, in particular well differentiated tumours takes into account that overexpression of  
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VEGF-A is an earlier event in tumour development as observed by its overexpression in CRC 
adenomas. On the other hand, the correlations observed with VEGF-C suggest that this marker was 
associated with more advanced stages and with histological characteristics that reveal a greater 
probability for metastization, as observed with the correlation with “Macroscopic Cancer type”, 
namely exophytic tumours; “Tumour Differentiation”, namely moderately differentiated tumours and 
“Tumour Penetration” and specifically more advanced tumour stages, T3/T4 lesions. Lastly, VEGFR-
3 correlated with the presence of “Hepatic Metastasis”. All these characteristics characterize a high 
expression of molecules that contribute for progression, invasion and metastasis and poorer survival 
and prognosis that we observed in overall-survival curves for rectal cancer in VEGF-C stage III and 
VEGFR-3 expression stage IV. 
 By documenting the overexpression of these markers in CRC, we can in the future improve 
CRC staging, by identifying at a early stage a group of patients that despite not present lymph node 
metastasis at diagnosis may present overexpression of these markers and so the potential for 
development of metastasis.  
 These findings also open a new door in CRC therapy. Most studies currently available are 
based on VEGF-A and VEGFR-2 expression on tumour cells and tumour vessels. With this study, also 
VEGF-C and VEGFR-3 are potential therapeutic targets, particularly if we associated the fact that the 
lymphatic pathway is a major route of escape in CRC and with the advantage of their expression in 
the tumour. Moreover, the fact that the drugs already approved and those that are under 
consideration are directed to VEGF-A and VEGFR-2 and resistance to these drugs are emerging, 
makes VEGF-C and VEGFR-3 promising new therapeutic options.  
 
 
The results presented in this chapter were published or submitted to international peer 
review periodicals: 
 
Martins SF, Reis RM, Rodrigues AM, Baltazar F, Filho AL.  Role of endoglin and VEGF family 
expression in colorectal cancer prognosis and anti-angiogenic therapies World Journal of Clinical 
Oncology. World Journal of Clinical Oncology. 2011;2(6):272–80. (Appendix 11) 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
_________________________________________________________________________
141 
 
 
 
Submitted for publication:  
 
Martins SF, Garcia EA, MA, Pardal F, Rodrigues AM, Filho AL. Clinicopathological correlation and 
prognostic significance of VEGF-A, VEGF-C, VEGFR-2, VEGFR-3 expression in Colorectal Cancer. 
 
 
Candidate to “Grande Prémio Fundação AstraZeneca 2008”: 
 
“Evaluation of Angiogenesis and Lymphangiogenesis in Colorectal Cancer: Impact in Prognosis 
Assessment”. PI: Sandra Martins. 
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Studies under development: 
 
As Master thesis of “Mestrado Integrado em Medicina” and other studies: 
 
- Assessment of D2-40 in CCR and correlation with clinicopathological data and prognostic 
significance. 
 
- Assessment of Ki-67 in CCR and correlation with clinicopathological data and prognostic 
significance. 
 
- Assessment of PROX-1 in CCR and correlation with clinicopathological data and prognostic 
significance. 
 
- Assessment of correlations between SPINT2 metilation, expression of the receptor MET, 
clinicopathological data and prognostic significance, in CRC. 
 
- Relevance of HOXA9 Expression in Colorectal Cancer Patients. 
 
- Assessment of Microsatellite Instability in Colorectal Cancer Patients. 
 
- miR-28 targets in colorectal cancer 
 
 
Candidate to RASPHAGY Project: 
 
- The role of KRAS mutation signaling in autophagy regulation in colorectal carcinoma: towards 
identification of new therapeutic targets. PI: Ana Preto. 
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“Protocolo de estudo de Cancro do Recto”
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 “Protocolo de Registo de Cancro Colorectal”
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             Appendix 4:  
“Protocolo Terapêutico de Cancro do Recto”
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Appendix 5: 
 “Protocolo de Follow-up de Cancro Colorectal”
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Appendix 6:  
“Protocolo de Registo de recidiva de Cancro Colorectal”
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Appendix 7:  
“Protocolo de Antibioprofilaxia para Cirurgia Colorectal”
    
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
    
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
    
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
    
 
 
   
_________________________________________________________________________
209 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 8:  
“Protocolo de Processamento da peça operatória”
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Appendix 9:  
“Sensibilidade da Ecografia Endorectal no estadiamento do Cancro do Recto: correlação com o 
estadiamento patológico.”
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of Colorectal Cancer Metabolic and Angiogenic Markers: Association with Clinicopathological Characteristics and Impact on Prognosis 
_______________________________________________________________________________________________________ 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
_________________________________________________________________________
225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 10:  
“Evaluation of quality parameters of rectal cancer surgery at the Coloproctology Unit of Hospital de 
Braga.”  
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Appendix 11:  
“Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic 
therapies World Journal of Clinical Oncology.”
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